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 Millions of people die every year because of infectious diseases, and 
malaria is among the top five of the deadliest infectious disease. In 2018, malaria took more 
than four hundred thousand lives, and more than half of them are children under five years 
of age. Most malaria-affected parts of the world are also the home of the most 
underprivileged people. Seemingly, antimalarial drug discovery never achieved the 
attraction that it requires. Like malaria, another infectious disease that is not extensively 
explored by drug discovery campaigns is American trypanosomiasis or Chagas disease. 
More than a hundred years have passed since discovering the disease, and surprisingly only 
two drugs are clinically available; both are far from ideal. It is imperative to say that these 
disease areas require more attention from drug discovery researchers. Hence, my project 
 v 
focuses on drug discovery for these neglected diseases utilizing one of the most prolific 
sources for lead molecule generation, marine cyanobacteria.  
This thesis describes the discovery of an N-methylated peptide, naranjamide, from 
a marine cyanobacterium collected in the Portobelo National Park, Panama. The compound 
inhibited the growth of Trypanosoma cruzi and Plasmodium falciparum parasites. To 
confirm the structure and established its antiparasitic potential, I attempted to synthesize 
the molecule and found the synthetic version to inhibit both T. cruzi and P. falciparum 
parasite with IC50 values of 9.2 μM and 2.8 μM, respectively. Later, a series of non-
methylated analogs were synthesized, which are found to be malaria selective. A more 
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Chapter I: Introduction 
1.1. History of natural product drug-discovery 
Bioactive natural products have been used for centuries by humans, with the first 
recorded example dating to around 2600 BC in Mesopotamia. Some of the earliest 
examples include cedar oil (Cedrus sp.), cypress oil (Cupressus sempevirens), licorice oil 
(Glycyrrhiza glabra), myrrh (Commiphora sp.) and poppy juice (Papaver somniferum), 
which are still employed for treating different illnesses today. Nearly all human 
civilizations documented their use of natural products for the remedy of illness. The 
Egyptian Ebers Papyrus, around 3500 years old, included approximately 800 prescriptions. 
Over 700 natural products are described in it, including Aloe (Aloe vera), Frankincense oil 
(Boswellia carteri), and Castor oil (Ricinus communis).1 Some other notable examples of 
texts on medicine, that registered bioactive natural products, include Corpus 
Hippocraticum by Hippocrates and other physicians, De Materia Medica by Dioscorides, 
Charaka Samhita from Indian Ayurveda, and Wu Shi Er Bing Fang (in English, 
Prescription for fifty-two diseases), the oldest book on Chinese traditional medicine.2-5  
The source of knowledge compiled in these texts came from people exploring the 
use of natural products while searching for answers to disease or sudden death.6 At that 
time, most of the researchers did not know that natural products contain bioactive 
molecules, which was the reason for their medicinal property. Few researchers 
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hypothesized that these natural products have different compounds responsible for their 
activity. In 1804, the hypothesis was proven when the German Pharmacist Friedrich 
Wilhelm Sertürner isolated the first pure natural compound, morphine from opium. In 
1827, Heinrich Merck commercialized morphine and made it the first commercialized 
medicine.7 Soon after, structure identification allowed scientists to synthesize many of 
these natural products and open a new research branch of chemistry, total synthesis. Many 
bioactive compounds of natural product origin were synthesized at that time, and the ability 
to make them synthetically has allowed their widespread use to be possible. It is worthy of 
mentioning some of these (Figure 1.1) : morphine (1.1) from Papaver somniferum (opium 
poppy), salicin (1.2) from Salix alba (white willow), strychnine (1.3) from Strychnos nux-
vomica (strychnos), quinine (1.4) from Cinchona ledgeriana (cinchona bark), colchicine 
(1.5) from Colchicum autumnale (colchicum), caffeine (1.6) from Coffea arabica, nicotine 
(1.7) from Nicotiana tabacum, atropine (1.8) from Atropa belladonna and cocaine (1.9) 
from Erythroxylum coca. Many of these molecules are still used for treating diseases or for 
other purposes.8 For example, colchicine is used for familial Mediterranean fever (FMF) 
and acute gout flares,9 and atropine is used as antidote for muscarinic agent 
(organophosphorus, carbamate, or muscarinic mushroom) poisoning and to treat 
bradycardia.10 Access to these natural products synthetically also allowed researchers to 
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modify their chemical structure in order to alter their pharmacokinetic and/or 
pharmacodynamic properties.11  
 
 
Until the 20th century, drug-discovery efforts principally explored terrestrial plants. 








































Figure 1.1: Historically significant natural products
 4 
last century and intensified the exploration of bioactive molecules from nature.12 Efforts 
by researchers have led to the discovery of numerous FDA approved new molecular entities 
(NME), semisynthetic natural compounds, and natural compound inspired synthetic 
compounds. The global medicine market is about 1.1 trillion USD, natural products and 
related compounds comprise about 35% of that market.13 Approximately 60% of small 
molecule therapeutics approved by the FDA in the last 40 years have origins connected to 
natural products.14 The FDA was established in 1906 to ensure the safety and effectiveness 
of human and veterinary drugs and vaccines and other biological products and medical 
devices intended for human use.15 Many natural products currently in use, including those 
mentioned above, were introduced to the clinic long before the FDA was established, and 
they became officially approved. For example, the semisynthetic plant derivative 
guaifenesin from guaiacum resin, got its official approval as a cough suppressant in 1852, 
though people used it as early as the 16th century. Since the establishment of the FDA, 
many new or existing natural products and their derivatives have been approved for clinical 
use.  
The most recent analysis by Newman and Cragg16 on natural products as sources 
of new drugs over the last four decades identified nearly half (930) of all FDA-approved 
drugs (1881) are either natural products, natural product derivatives or inspired by natural 
products. Among these approved natural products, 71 are unmodified natural products, and 
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356 are natural products derivative. Remaining 503 drugs include natural products and 
synthetic drugs with natural product pharmacophores or mimic of natural product. An 
earlier analysis by Patridge et al.17 revealed that 44% of approved were derived from 
mammals (Bovine, porcine, equine, canine, and human). Among the non-mammalian 
natural products (NMNP), almost half (45% of NMNPs; 25% overall) of them are plant-
derived. Two other significant sources of NMNP include bacteria (29% of NMNPs; 16% 
overall) and fungi (22% of NMNPs; 12% overall). Unfortunately, rigorous procedures to 
isolate and identify natural products, complexity of the molecules making total synthesis 
difficult, advances in both high throughput screening (HTS) and combinatorial synthesis, 
contribute to the shifting of drug discovery campaigns by many pharmaceutical companies 
away from natural products to synthetic compounds.17-18 Nevertheless, natural products 
and their derivatives are still the most diverse sources for chemical entities to treat diseases 
or to elucidate disease mechanisms. A cheminformatic analysis on a representative set of 
natural products, bioactive molecules, and synthetic compounds has found that the 
chemical diversity possessed by natural products covers a large and diffuse area in the 
chemical space as compared to the synthetic compounds which are concentrated, hence 
less diverse.19  
The history of medicine is full of exciting tales glorifying the impact of natural 
products chemistry in drug discovery. In general, natural products show high selectivity 
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and affinity for their specific biological target.20 Today much of what we know about 
neurochemistry and the function of the central nervous system (CNS) has been aided by 
the use of natural products. Many of the receptors within the CNS were discovered by 
studying their interactions with natural products. For example, research on opium alkaloids 
from Papaver somniferum guided researchers to the discovery of the opioid receptors and 
has helped to elucidate the mechanism of antinociception mediated by these receptors. In 
this case, ethnopharmacological knowledge has aided the identification and study of the 
terrestrial natural product morphine.21 Another inspiring story for natural product research 
is the discovery of ivermectin and artemisinin. In 2015, the Nobel prize in Physiology and 
Medicine was awarded to William C. Campbell together with Satoshi Ōmura “for their 
discoveries concerning a novel therapy against roundworm infections” and to Tu Youyou 
"for her discoveries concerning a novel therapy against malaria".22  
Both ivermectin (1.11) and artemisinin (1.12) were discovered when researchers 
were searching nature for the arsenals to fight helminthiasis and malaria, respectively. 
Ivermectin resulted from a collaborative effort by Campbell and Omura from Merck 
Research Laboratories and Kitasato Institute, respectively, where they searched 
microorganisms for compounds with the anthelmintic property. Both Campbell and Omura 
were motivated by their philosophy about natural product chemistry. Campbell believed in 
nature’s ability to produce compounds beyond human imagination, and Omura considered 
 7 
microorganisms and microbial compounds as “splendid gifts.”18 During the COVID-19 
pandemic, ivermectin draws significant attention from clinicians when researchers from 
Royal Melbourne Hospital and Monash University published the in vitro efficacy of 
ivermectin in the inhibition of SARS-CoV-2.23  
 
Tu Youyou was a phytochemist and the head of the malaria research group at the 
China Academy of Chinese Medical Sciences. Belief in the wisdom of traditional Chinese 
medicine inspired her to discover artemisinin. She described artemisinin as “the gift from 
Chinese medicine.” Awarding Nobel prizes to natural product researchers certainly 
















R = C2H5 or CH3
X-Y = C2H2
Ivermectin (1.11)













Figure 1.2: Discovery of Avermectin and Artemisinin. (Image recreated and modified from reference 18 by ChemDraw 18.1.
(A) avermectin-producing S. avermitilis was isolated from soil, from which avermectins were discovered and later developed 
into ivermectin (1.11). 




advancement in other areas of sciences like genomics, synthetic biology, metabolomics, 
bioinformatics, and analytical techniques, which could aid in exploring bioactive NP, 
researchers are now anticipating an imminent golden age of NP drug discovery.18, 24-25 This 
will undoubtedly motivate young investigators who want to pursue their research career in 
natural product chemistry.   
1.2. Marine natural products 
The marine environment is the sanctuary of numerous organisms. They survive in 
diverse and hostile surroundings by producing an abundance of secondary metabolites with 
various bioactivities.26 In comparison with terrestrial sources, there are very few 
ethnopharmacological reports about marine source organisms. A few notable examples 
include red algae Chondrus crispus and Mastocarpus stellatus as the remedy for colds, 
sore throats, chest infections, kidney trouble and burns, and red algae Porphyra umbilicalis 
for relieving indigestion. The species being investigated for bioactive marine natural 
products (MNPs) include marine microorganisms (bacteria, fungi, cyanobacteria, 
dinoflagellates), algae, sponges, cnidarians, bryozoans, molluscs, tunicates, echinoderms, 
mangroves, and other intertidal plants and microorganisms.27 Despite covering two-thirds 
of the earth’s surface, extensive exploration of the marine environment as a potential source 
of medicine started only in the mid-1970s aided by the introduction of SCUBA. Thousands 
of structurally unique bioactive metabolites have been reported from the marine 
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environment since then.6 More than 32,000 articles have been indexed in the 
comprehensive database dedicated to marine natural product (MNP) research, MarinLit, 
after its establishment in 1970 by Professors John Blunt and Murray Munro at the 
University of Canterbury, New Zealand.28 Natural Product Atlas, another online database 
of microbially derived natural product, lists 9764 compounds from the bacterial origin and 
the cyanobacterial genus Lyngbya is the fourth highest producer in their database of natural 
products among all bacterial genera.29 Bioactivities of MNPs cover a diverse range of 
diseases including antibacterial, antifungal, antiviral, antiparasitic, antitumor, anti-
inflammatory, antioxidant, and immunomodulatory activities.30-32  Apart from providing 
bioactive molecules, MNPs have started to find their application in therapeutics. As of 
November 2019, ten MNPs or MNP derived natural products are approved by the FDA 
(Figure 1.3). Of these, two are the original natural product as isolated, and the remaining 
compounds are synthetic agents with origin related to MNPs.33 
Cytarabine (Ara-C; 1.13), an anticancer agent, is the first FDA approved marine 
derived drug. A similar analog is the antiviral vidarabine (Ara-A; 1.14) and both are 
synthetic analogs of a marine sponge derived nucleoside spongouridine.  The NP was 
isolated from the Caribbean sponge Tethya crypta (Tethylidae).34 The compound intrigued 
researchers when they observed the free form of this nucleoside outside the nucleus, though 
their natural analogs, purines, and pyrimidines, are bound to DNA and RNA. This 
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observation led to the idea that the sponge uses this compound for chemical defense. 
Vidarabine was the first marketed antiviral agents. Though vidarabine is clinically useless 
now because of poor solubility and toxicity, and the development of safer antivirals,35 
cytarabine is still in the market. In fact, the latter is the best approach (7+3 protocol) 
currently available to treat acute myelogenous leukemia, where the patient is treated with 
cytarabine for seven days continuously via intravenous administration. The first three days 
of the treatment also use intravenous daunorubicin, hence the nickname “7+3” protocol.36    
Twenty years after the approval of those nucleosides, the FDA approved Ziconotide 
(1.15), a synthetic form of ω-conotoxin MVIIA. Ziconotide is one of the three approved 
analgesics that act on N-type calcium channels (Cav2.2). This drug is instrumental in 
managing severe chronic pain associated with cancer and neuropathies. MVIIA was 
isolated from Conus magus in 1979. It is a 25 amino acid linear peptide, containing three 
disulfide crosslinks, that inhibits Cav2.2.21 The inspiration behind this discovery was the 
findings that cone snail venoms are lethal and that they use their venom for hunting fish.  
Extensive research led to the discovery of several biologically active conotoxins, most of 










































































































































































Figure 1.3: FDA approved MNPs or MNP derived natural products
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The first European Union approved marine anticancer agent is ecteinascidin 743, 
also known as trabectedin or ET-743 (1.16). It was isolated from the Caribbean tunicate 
Ecteinascidia turbinate and has been used for the treatment of ovarian cancer and soft 
tissue sarcoma.38 Ecteinascidin is a tetrahydroisoquinoline alkaloid and is currently 
produced synthetically. It is a DNA alkylating agent, and unlike traditional alkylating 
agents, it binds to the minor grove of DNA.39   
 A structurally simpler version of the polyketide halichondrin B resulted in the 
anticancer agent eribulin mesylate (1.17). Halichondrin B was isolated from the marine 
sponge Halichondria okada. The total synthesis of Halichondrin B by the Kishi 
laboratory allowed researchers to explore many of its analogs, which resulted in the 
discovery of eribulin.40 Both eribulin mesylate and halichondrin B act via tubulin 
inhibition by binding at the vinca site of b-tubulin.41  
Omega-3 fatty acids from marine fish are well known for their lipid-lowering 
property and are used in combination with diet and/or other lipid-lowering agents.42 The 
marketed drug Lovaza contains a combination of the ethyl esters of eicosapentaenoic acid 
and docosahexaenoic acid (1.18). Anchovies, herring, salmon, mackerel, smelts, and jacks 
from the South Pacific Ocean are commonly the sources of these oils used to make 
commercial products.41  
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The most recently approved anticancer drug related to MNP is brentuximab vedotin 
(1.19). It is an antibody-drug conjugate, where the drug part is the pentapeptide 
monomethyl auristatin E (MMAE) (1.21), a derivative of the MNP dolastatin 10 (1.20). 
Dolastatin 10 (1.20) has potent antitumor activity and was initially isolated from the sea 
hare Dolabella auricularia.43 Interestingly, the origin of dolastatin 10 was later identified 
as the sea hare’s cyanobacterial diet, Symploca hydnoides.44 A detailed discussion about 
compound 1.20 and 1.21 is described in section 1.2.1. 
In the first 35 years of marine drug discovery, only four products reached the 
market. However, within the next 15 years, the number of approved drugs reached ten. In 
addition to these, 27 more compounds are at different stages of clinical trials. The most 
prevalent indication for these compounds is for cancer, and others have been developed for 
cognition and schizophrenia, wound healing, and Alzheimer’s disease.33, 36 
1.2.1. Marine cyanobacteria as the source of bioactive compounds 
Cyanobacteria are a group of gram-negative prokaryotes that are capable of 
performing oxygenic photosynthesis, a unique ability among prokaryotes.45 They are 
approximately 2.6 to 3.5 billion years old, making them one of the earliest photosynthetic 
organisms.46 They can exist in various forms like unicellular, filamentous, planktonic or 
benthic, and colonial.45 Cyanobacteria are the most ubiquitous photosynthetic organisms, 
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and they can be found almost everywhere, i.e., marine, freshwater, and terrestrial 
environments.47  
Researchers considered cyanobacteria as a potential source for bioactive NP, when 
it was discovered that freshwater genera Nostoc had been used long ago to treat gout, 
fistula, and several other diseases. The field of marine cyanobacterial drug discovery 
became prominent became emerging since the 1990s after the extensive exploration 
initiated by RE Moore and WH Gerwick.48 Marine cyanobacteria have drawn the attention 
of NP chemists because of their ready availability, rapid growth and diversity, their role in 
the surrounding environment, and their ability to provide highly bioactive secondary 
metabolites.49 Marine cyanobacteria achieve this abundance of chemical diversity via 
complex approaches that utilize mainly polyketide synthases (PKS) and nonribosomal 
peptide synthases (NRPS) as their biosynthetic tools.50 Apart from potent toxins, marine 
cyanobacteria produce an abundance of exciting molecules with a wide array of activities 
like anticancer, antifungal, anti-HIV, antimicrobial, immunosuppressant, anticoagulant, 
anti-inflammatory, antiprotozoal, antimalarial, antiviral, and antitubercular activities.51-55 
Compounds exhibiting these activities are mostly isolated from the genera Oscillatoriales, 
Lyngbya, Moorea, Okeania, and Caldora.56-57  
An analysis of all MNPs and related compounds, approved by the FDA and in 
clinical trials,33 revealed that more than half of them (57%) have marine cyanobacteria as 
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their source organism (Figure 1.4A). Among the ten products already approved (Figure 
1.4B), one-third of them have links associated with marine cyanobacteria. Whereas two-
third of the MNPs and related compounds in clinical trials come from marine 
cyanobacteria. This statistic is quite encouraging as among a multitude of marine sources, 
a single class of organisms, cyanobacteria, promises a majority of products with the 
potential to reach the clinic. 
 
   
The marine cyanobacterial compound that has attracted the most attention is 
dolastatin 10 (1.20). Though this compound is not directly used in clinics, it has inspired 
the development of monomethyl auristatin E (MMAE) (1.21) and monomethyl auristatin 
F (MMAF) (1.22) which are the active warheads of several antibody-drug conjugates 
(Figure 1.5). Some of these conjugates are already clinically approved and/or in clinical 
trials. Dolastatin 10 was fist isolated in 1972 from the hare Dolabella auricularia in the 
Figure 1.4: FDA approved marine drugs: cyanobacteria vs. others (Plots are generated based on 



























Indian Ocean. Petit et al.58 found that extracts obtained from that marine organism were 
very effective against the National Cancer Institute’s (NCI) murine P388 lymphocytic 
leukemia cell line. Fifteen years of continuous work led to the isolation and structure 
determination of the unique linear pentapeptide Dolastatin 10. This extremely potent 
cytotoxic compound was isolated in an extremely low yield (10-6 to 10-7%) from the sea 
hare. However, Luesch et al.44 discovered dolastatin 10 from the Palauan marine 
cyanobacterium Symploca sp. VP642, thus building up the rationale that a cyanobacterium 
is the original producer of this compound. Dolastatin 10 ended up in the sea hare as a result 
of the consumption of cyanobacteria by the animal as food. Dolastatin 10 exhibits its anti-
tumor effect by disrupting the microtubule assembly.59 It also inhibits BCL-2 protein via 
phosphorylation and induces apoptosis.60  Attempts to explore the SAR of dolastatin 10 
resulted in several useful bioactive analogs, most notably monomethyl auristatin E 
(MMAE) and monomethyl auristatin F (MMAF), where the C-terminus dolaphenine 




The first mAb-linked auristatin derivative is brentuximab vedotin (1.13) by Seattle 
Genetics where MMAE (1.21) is linked to the chimeric anti-CD30 antibody CAC10 (SGN-
30) by a valine-citrulline linker and a self-immolative spacer, p-aminobenzyloxycarbonyl 
(PABC).62 The stable dipepetide, valine-citrulline, is readily cleavable by the lysosomal 
enzyme cathepsin B. The spacer PABC facilitate the proteolysis by keeping the drug away 
from the proteolytic site.63 Once the peptide is cleaved by the cathepsin B, the PABC group 
rapidly cleaved via 1,6-elimination and released the MMAE in the tumor 
microenvironment (Figure 1.6). 
Besides anticancer molecules, marine cyanobacteria possess compounds with many 













































Figure 1.5: Development of MMAE (1.21) and MMAF (1.22) from dolastatin 10 (1.20)
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macromolecules. Notable antimalarial compounds from marine cyanobacteria are 




1.3. Tropical diseases 
According to the World Health Organization (WHO), the diseases that occur mostly 
in tropical regions are called tropical diseases, which are common infectious diseases that 
























































Figure 1.6: Mechanism of Action of Brentuximab vedotin (1.19).
 19 
lymphatic filariasis, Chagas disease, African trypanosomiasis, and dengue. These diseases 
generally involve a non-mammalian vector that carries the causative organism (parasite, 
bacteria, or virus) and transmits the disease to humans upon biting. These diseases affect 
more than 1 billion people, mainly the most impoverished population of the developing 
world living in places infested heavily by the infective vectors. Many of these tropical 
diseases do not draw much attention from the developed world because of the poor 
socioeconomic condition of the affected population,64 authentic data unavailability, and 
difficult to pronounce the name and hence called neglect tropical diseases.65   
 Discussion on all the tropical diseases is beyond the scope of this chapter. I will 
focus on malaria and Chagas disease (American trypanosomiasis) as our drug discovery 
effort resulted in the discovery of a marine cyanobacterial metabolite with activity against 
parasites for those diseases.  
1.3.1. Malaria 
Malaria is a life-threatening vector-borne disease caused by five species of 
Plasmodium parasites that are transmitted via the bites of infected female Anopheles 
mosquitoes. Among the five species, P. falciparum and P. vivax are the most dangerous. 
P. vivax is predominant in the Americas, whereas P. falciparum rules the rest of the world.66 
Malarial patients typically manifest fevers, sometimes associated with chills, 
headache, and other febrile symptoms. Once an infected female Anopheles mosquito bites 
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someone, the parasites pass to the human host, reproduce via sexual reproduction, and 
initiate the pre-erythrocytic phase by infecting the liver (Figure 1.7). There they develop 
into schizonts and rupture hepatic parenchymal cells to release merozoites. Then 
merozoites enter the erythrocytic phase and multiply via asexual reproduction to produce 
and release more merozoites. The clinical manifestations of malaria appear in this 
erythrocytic stage.67 It is difficult to recognize the early signs of malaria, which are often 
mild, and this makes it a difficult disease to treat. The disease usually progresses to severe 
conditions and may be fatal if not treated within 24 hours. Multiorgan failure is common 

















































Figure 1.7: The life cycle of malaria parasite (Recreated and modified by ChemDraw 18.0 from 
Kumar et al.67)
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Despite clear understanding of the diseases, vectors, and parasites, malaria is still 
one of the major fatal illnesses of the world. It is the 6th leading cause of death in low-
income countries.68 The burden of malaria on the US is small, about 2000 cases each year, 
according to the CDC,66, but some parts of the world are suffering heavily, especially 
Africa. According to the World Malaria Report 2019, published by WHO,69 every year of 
the last decade has seen more than 200 million patients worldwide (Figure 1.8).  
 
Though mortality due to Malaria is reducing every year, the number is still high, a 
staggering 405,000 deaths in 2018. Ninety-five percent of those patients belong to Africa 
and India. Malaria is deadlier for children under five years old, and they constituted 67% 
(272,000) of total deaths in 2018. What is not visible from the chart is, the primary 
contributor to child mortality is the premature delivery of babies with low birth weight due 
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Figure 1.8: Total infected and total deaths due to malaria from 2010-2018. (Plots are generated on the basis of 
WHO World Malaria Report 2019.69)
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a high risk of malaria. I have seen how poor hygiene, lack of sanitation, and inefficient 
public health policies make that region an excellent breeding ground for mosquitoes, and 
aid in spreading of malaria, and other mosquito-borne diseases like Dengue fever and 
Chikungunya. Approaches to control malaria focuses on managing the vector and also 
providing effective therapy for patients, which is particularly important because of the high 
number of deaths worldwide. It is imperative to say death by malaria has reduced with the 
discovery of artemisinins. Still, researchers are skeptical because of the chance of 
emergence of resistant strains against artemisinins and occurrences of reinfection because 
of the inability to eradicate malaria vector in poor countries. It is possible in the near future 
that the world will be helpless without new agents in hand.70 It emphasizes the urgency of 
new antimalarial drug development.   
1.3.1.1. Antimalarial agents 
Based on their structural class and mechanism of action, commercially available 
antimalarial drugs (Figure 1.9) can be broadly classified into three groups:71-72 
1. Quinoline derivatives/aryl amino alcohol compounds: quinine (1.4), 
mefloquine (1.23), halofantrine (1.24), lumefantrine (1.25), chloroquine (1.26), 
amodiaquine (1.27), cyloquine (1.28), primaquine (1.29)  
2. Antifolate compounds: proguanil (1.30), pyrimethamine (1.31), trimethoprim 
(1.32).  
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3. Artemisinin compounds: artemisinin (1.12), artesunate (1.34), artemether 
(1.35), arteether (1.36)  
In section 1.1, a discussion has been made about artemisinin derivatives, which are 
the most effective antimalarials currently used in several combination therapies. 
Interestingly, the first chemotherapeutic agent effective against malaria, quinine (1.4), was 
also isolated from a natural source, the bark of the cinchona tree in 1820. The plant 
cinchona contains other quinoline alkaloids like quinidine, cinchonine, and cinchonidine, 
which are also effective against malaria. Quinine was the first successful example of a 
chemical compound to treat an infectious disease.73 Due to the high toxicity associated with 
quinine therapy, new molecules were developed to control malaria. The first synthetic 
antimalarial drug, methylene blue (1.33), synthesized by Paul Ehrlich in 1891, was used in 
the late 19th and early 20th centuries against all types of malaria. Methylene blue was used 
widely because the then primary medicine, quinine, was in limited supply as it could only 
be obtained from the natural sources. Methylene blue was later discontinued because of the 
discovery of safer agents. However, it recently gained interest from malaria researchers 
because of its effectiveness in combination chemotherapy.74 
Due to concurrent hepatic and erythrocytic episodes in the same patient and 
unavailability of a single agent to kill both tissue schizonts and blood schizonts, 
antimalarial drugs are used in combination. These drugs target different signalling 
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pathways of the Plasmodiam paracite. For example, quinnine and most of the quinoline 
alkaloids are lethal to blood schizonts only and inhibit them by binding with the toxic heme 
(ferriprotoporphyrin IX). Heme is the digestive end product of hemoglobin which is 
sequestered by histidine rich protein and lipids to insoluble, chemically inert hemozoin. 
Drug binding to heme resulted in the prevention of sequestration. The resulting heme 
buildup causes oxidative damage to membranes, digestive proteases, or other critical 
biomolecules of paracites. Drugs like proguanil, pyrimethamine and trimethoprim 
selectively inhibit Plasmodium dihydrofolate reductase (DHFR) and thereby inhibit the 
biosynthesis of nucleic acid.  
Also, some highly potent antimalrial drugs’, like primaquine (acts against primary 
and latent hepatic stage), mechanism of action is poorly unnderstood. One hypothesis about 
primaquine is that it converts to highly reactive oxidative inntermediates to exert toxicity 
or may inhibit protozoal electronn transprot chain.75  
Several natural and synthetic molecules have been developed after the discovery 
of quinine, but the emergence of resistant parasites makes their use restricted to particular 
situations. The threat of resistant pathogen emergence will eliminate the success of the 






















































































Figure 1.9: Commercially available antimalarial drugs.
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1.3.1.2. Antimalarial agents from marine cyanobacteria and other marine sources 
All antimalarials isolated from marine sources can be broadly classified into five 
categories: (i) isonitrile containing derivatives; (ii) alkaloids; (iii) endoperoxides; (iv) 
peptides, and (v) quinones and phenols.76 The first marine antimalarial drug discovered 
was aplasmomycin A (1.37). It was isolated from a strain of Streptomyces griseus found in 
shallow sea sediment in Sagami bay. Among marine antimalarial compounds, manzamines 
(complex polycyclic (7–8 rings or more) alkaloids) are the most potent antimalarials 
comparable to currently available drugs.77  
 
Since the discovery of manzamine A (1.38), the first compound from this class 
isolated from an Okinawan sponge in 1986, more than 60 manzamines have been reported. 





















Figure 1.10: Aplasmomycin A (1.37) and Manzamine A(1.38)
1.37 1.38
 27 
This finding leads researchers to speculate that manzamines have a symbiotic origin. Later 
Micronosphora sp was identified as a manzamine producing bacteria.76 Besides 
antimalarial activity, manzamines are also known to possess anti-inflammatory, antifungal, 
antibacterial, and antitubercular activity and activity against AIDS opportunistic 
pathogens. 78-81 
An analysis of compounds82-84 isolated from marine cyanobacteria in the 21st 
century revealed that the majority of the antimalarials isolated from marine cyanobacteria 
are peptides (Figure 1.11). In the linear depsipeptide series, gallinamide A (1.39) was 
isolated from a Schizothrix species obtained from rocky reef near Piedras Gallinas near 
Portobello on the Caribbean coast of Panama.85 Moorea producens is known to produce 
the antimalarial lipopeptides, named dragonamides A (1.40), B (1.41) and E (1.42), 
carmabin A (1.43) and dragomabin (1.44).86-87 Among cyclic peptides,  lagunamides A-C 
(1.45 - 1.47) from Lyngbya majuscula and venturamides A-B (1.48 – 1.49) from 
Oscillatoria sp. were found to be active against malaria parasites.88-90 Shao et al.91 
discovered a unique polyhydroxy macrolide with a 40 membered lactone ring from 
Okeania hirsute, collected from the Caribbean coast of Panama. The compound, 





Clearly, antimalarial drug discovery is downplayed in comparison to other drug 
discovery campaigns. Drug exploration for potential antimalarial lead is extremely 
important to develop new drugs that could overcome the problem of resistance emergence, 
the high toxicity of most commonly known drugs, and to provide insights about 
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Figure 1.11: Antimalarial drugs from marine sources.
 29 
a promising source of antimalarial lead discovery and provided compounds with nanomolar 
potency (IC50) against the malaria parasite. For example, manzamine A has IC50 values of 
8.2 nM and 15 nM against chloroquine-sensitive and chloroquine-resistant P. falciparum 
strains, respectively.77 Overall, antimalarial drug discovery form marine natural products 
has potential for eliminating this deadly disease from this world.  
1.3.2. Chagas disease 
Chagas disease (CD), also known as American trypanosomiasis, is named after the 
discoverer of the illness Carlos Chagas and is caused by the parasite Trypanosoma cruzi. 
It is transmitted to animals and people by triatomine bugs (or “kissing bug”) and is endemic 
in the poverty-affected rural Latin America.92 Once an infected bug bites a human, it 
releases trypomastigotes in its feces which then enters the human host through the injury 
or mucosal membrane. After transforming into intracellular amastigotes, followed by 
multiplication by binary fission, they are released from the infected cell into the blood as 
trypomastigotes. From there, they can infect other cells or may be transferred to another 
uninfected kissing bug when it takes a blood meal (Figure 1.12). Clinical manifestations 
appear when the trypomastigotes burst out of the cells into the blood.  
The disease propagates in two phases. The acute phase may be asymptomatic in 
most cases. However, some patients may show acute symptoms like fever, headache, skin 
lesions, unilateral palpebral edema, lymphadenopathy, hepatosplenomegaly, pallor, 
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breathing difficulty, and abdominal or chest pain.93-94 The acute phase resolves 
spontaneously within 4-8 weeks, and at this point, the number of circulating parasites in 
the blood drops at a level undetectable by microscopy. If untreated, the patient enters the 
chronic phase without any sign or symptoms. Decades after the onset of acute infection, an 
average of 20% of patients suffer severely due to cardiomyopathy, or megaesophagus, or 
megacolon. The cardiac involvement is more frequent than gastrointestinal involvement. 
CD is the principal cause of infectious cardiomyopathy.95  
 
 
CD is prevalent over a wide geographical area of the Americas, covering the 
southern USA, Central America to the north of Argentina, and Chile. The CD control 
Figure 1.12: The life cycle of T. cruzi (obtained from CDC; labeled for non-commercial
reuse).92
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programs took several initiatives like vector control programs, blood bank screening, and 
in some countries, congenital CD screening programs that lower the burden effectively.96 
There was a three-fold decrease in the total number of infected people from the 1980s to 
2010. Simultaneously, the death rate decreased as well. Though the overall picture is a 
success story, there are pockets in these regions where transmission has increased.94 Drug 
discovery research for CD seriously lacks the attention of the scientific community. CD is 
one of the most neglected among NTDs. It is evident from the fact that there are only two 
drugs in the market, and people have to rely on them despite their toxicity. 
1.3.2.1. Drugs for Chagas Disease and marine natural products: 
Nifurtimox (1.51) and Benznidazole (1.52) are the currently available medicines 
used to treat CD. Nifurtimox was introduced in the late 1960s to treat CD. In the US, it is 
regulated by the CDC only under investigational protocol and is not approved by the FDA. 













Figure 1.13: Clinically approved CD drug
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The mechanisms of action of these drugs are different. Nifurtimox inhibits the 
pyruvic acid synthesis and thus kills T. cruzi by inhibiting carbohydrate metabolism.  
Benznidazole is a prodrug, which becomes activated by the parasite enzymes and the active 
metabolites inhibit glutathione and trypanothione of T. cruzi.96  
 
A review on trypanocidal marine natural products published by Jones et al.97 
classified anti-CD compounds into four subclasses: (i) terpenes; (ii) polyketides and 
xanthones; (iii) alkaloids and (iv) peptides. The most potent marine natural product 
reported was pandaroside G (1.53; T. cruzi IC50=0.77 µM), which was isolated from the 
Caribbean sponge Pandaros acanthifolium.98 Unfortunately, the molecule lacks selectivity 
since it also inhibited mammalian L6 cells (IC50= 0.22 µM). The most active and selective 
marine compound reported against T. cruzi was chaetoxanthones C (1.54; IC50= 38 µM; 






















Figure 1.14: Pandaroside G (1.53) and Chaetoxanthones C (1.54)
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marine-derived fungus Chaetomium sp.97 Considering the need for new and safer 
therapeutic agents for CD, a more extensive search should be conducted exploring all 
viable sources. Marine sources are very promising in this regard, as they are known to 
produce a multitude of compounds having antiprotozoal activity.  
1.4. Conclusion 
 The most innovative and efficient synthetic chemistry laboratory is not located in 
any academic or industrial setting; it is in nature. With that inspiration, we explore oceans 
in search of the cure for diseases that do not draw much attention from the pharmaceutical 
industry. Many drug discovery stories start with the gift from nature, and then the human 
brain takes that lead to find cures for diseases. Lead discovery is the main objective of our 
natural product chemistry research. This lead molecule may help us developing a cure for 
neglected tropical diseases or may aid in elucidating information about a potential target.  
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Chapter II: Isolation, Structure Elucidation and Total Synthesis of Naranjamide 
2.1 Introduction 
The field of marine drug discovery came forth as an alternate source of bioactive 
natural products besides terrestrial compounds in the 1940s and, on an average, has 
provided more than 28,000 novel compounds each year.99 From 2007 to 2016, more than 
400 new natural products have been isolated from marine cyanobacteria, with 126 peptides 
and peptide-related structures, of which 39 are linear peptides.56 Unlike other marine 
sources, harvesting cyanobacteria does not represent a threat to the environment since 
cyanobacteria combine the ability of rapid growth, genetic tractability, and cultivability, 


















































Figure 2.1: Antiparasitic compounds isolated from Panamanian cyanobacteria.
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bioactivities includes, but is not limited to, anticancer, antibacterial, antifungal, 
antiprotozoal, antiviral, immunomodulation, and cytotoxic activities.48 
  Every year neglected tropical diseases (NTDs) impose billions of dollars of 
economic burden on developing countries and affect more than one billion people in 149 
countries.100 Populations living in poverty with poor hygiene as well as exposure to 
infectious vectors, domestic animals, and livestock are the most affected by NTDs.101 
Effectiveness of available medications is restrained by the emergence of resistant 
pathogens and severe side effects associated with therapy. Since these diseases do not 
possess a significant threat to the population of developed countries, and financial return 
is minimal, the pharmaceutical industry is less focused on developing new agents for these 
diseases.102 In recent years, several marine cyanobacterial metabolites with antiprotozoal 
activity have been reported. Lipopeptides like dragonamide A (2.1), dragonamide E (2.2), 
and carbamin A (2.3), isolated from Lyngbya majuscula,86-87 and the linear peptide 
gallinamide A (2.4), isolated from Schizothrix sp.,85 (Figure 2.1) are some notable 
examples with antiparasitic activity. We aimed to explore Panamanian marine 
cyanobacteria as a potential source of bioactive compounds that can produce molecules 
with activity against NTDs. 
In 2012, an orange cyanobacterial mat was collected from Portobelo, Panama. 
Bioactivity-guided fractionation of this cyanobacterial mat resulted in the discovery of an 
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N-methylated pentapeptide (2.5), which inhibited the growth of T. cruzi and P. falciparum 
parasites. Using 1D and 2D NMR (Section 4.6.3), the structure was determined to be a 
linear peptide where the N-terminus contains an N, N-dimethyl-valine moiety, followed by 
a valine, N-methyl isoleucine, N-methyl valine and N-methyl dolaphenine at the C-
terminus. MS-MS analysis confirmed the amino acid sequence of the structure. The 
compound was given the trivial name Naranjamide since the crude cyanobacterial mat was 
orange in color, and the Spanish name for the color orange is Naranja. My contribution to 
this project was to conduct a total synthesis of naranjamide, which also showed growth 
inhibition of T. cruzi and P. falciparum, and confirmed the antiparasitic potential of the 
compound. 
This chapter describes the discovery, structure elucidation, and attempts at the total 
synthesis of the molecule and studies to confirm its potential as an antiparasitic compound.  
2.2 Discovery of naranjamide 
An orange cyanobacterium collected by hand using SCUBA in Portobelo, Panama, 
was extracted using a 2:1 dichloromethane: methanol mixture to yield an extract (4.2 g) 
and given the in-house extract code A2002 (Figure 2.2). The extract was tested for its 
antiprotozoal activity and was found to inhibit P. falciparum growth (82.6%). The extract 
was then fractionated (Figure 2.2) by silica vacuum chromatography and the fraction 
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(2002H) obtained with 1:1 ethyl acetate: methanol inhibited the growth of both P. 
falciparum (97.5%) and T. cruzi (75%).  
Further fractionation of 2002H by C18 Sep-Pak yielded the fraction 2002H4, 
eluting with 80% methanol in water, which showed an increment of T. cruzi growth 
inhibition (81.5%) while retaining P. falciparum growth-inhibiting (79.6%) activity. 





Naranjamide (2.5) was isolated as a clear solid. Its molecular formula was 
determined as C37H60N6O4S by HRESIMS (m/z 685.44576 [M+H+], calcd. 684.9751]  
(Figure 4.1), indicating the presence of 11 degrees of unsaturation. Following the 
interpretation of 2D NMR experiments (Table 2.1), 1H and 13C NMR were assigned to the 
subunits constituting naranjamide, namely dolavaline (C-17 to C-21), valine (C-14 to N-
16), N-methyl isoleucine (C-11 to N-13), N-methyl valine (C-8 to N-10) and dolaphenine 
(N-1 to N-7). The amino acid sequence was later confirmed by tandem MS-MS analysis. 
Naranjamide (2.5) is a linear peptide with a dolaphenine residue at the N-terminus, a 
common privileged structural unit of bioactive natural peptides, where the peptide chain 
ends at a des-carboxy thiazole functionality.103 COSY spectrum clearly showed the 
correlation between the alpha proton (C-6; δH = 6.60) and two benzylic protons (C-6a; δH 
= 3.30 and 3.69) of the dolaphenine moiety. Corresponding HSQC correlations identified 
the alpha carbon (C-6, δC = 54.34) and the benzylic carbon (C-6a, δC = 36.05). Proton 
signals between 7.25 to 7.77 represent the phenyl and thiazole moiety of dolaphenine. Both 
HMBC and NOESY data correlate H3-7a (δH = 2.88) with C-6 and C-8 (δC = 169.91) and 
with H-6 and H-6a, respectively. These correlations indicate an N-methyl amide adjacent 
to C-6. Multiple other N-methyl amide functionalities have also been observed and 
identified naranjamide (2.5) as an N-methylated peptide. There is only one non-methylated 
amide where NH-16 (δH = 6.95) belongs to a valine moiety. 
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COSY and NOESY correlations (Figure 2.3) with NH-16 identified the alpha 
proton H-15 (δH = 4.85, δC = 53.32) and the beta proton H-15a (δH = 1.94, δC = 30.71), and 
the HMBC spectra linked H-15 and C-14 (δC = 172.60). This valine was identified as the 
penultimate residue as it was adjacent to the N, N-dimethyl valine residue on its N-terminal. 
Proton peaks of N, N-dimethyl (C-18bc) were not distinguishable as a singlet 
because of overlapping with beta proton (9a) signals. The HSQC (C-18bc, δH = 2.30, δC = 
42.79) suggested the presence of N-alkyl amine. From NOE data, it was seen that these 
alkyl protons are correlated with an alpha proton (C-18, δH = 2.49, δC = 76.50) and NH-16, 
thus suggesting the connection between an N- alkyl valine and valine moieties. The 
presence of N, N-dimethyl valine was later confirmed from fragment mass analysis (Figure 
2.4). HMBC correlation of H-13a (δH = 3.04) with C-14 (δC = 172.60) and C-12 (δC = 














































Figure 2.3: Key 2D correlations for determining the structure of naranjamide (2.5)
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(δH = 1.94) connects the penultimate valine with an N-methylisoleucine on the other side. 
The later residue was followed by N-methylvaline, as HMBC correlations were seen 
between H3-10a (δH = 2.46) and C-9 (δC = 58.29) and C-11 (δC = 169.74), and NOE showed 
correlations of H3-10a with H-9 (δH = 5.06). The HMBC correlation between H-9 and C-8 
connects this N-methylvaline with the terminal N-methyldolaphenine moiety and thus 
completes the sequence. The alkyl side chains of amino acid residues were not 
distinguishable as they resonate inn close proximity. Thus MS-MS analysis (Figure 2.4) 
aided in the confirmation of the individual residues and their sequences. 
In general, linear peptides with 2-10 amino acid residues are flexible.104 N-
methylation on peptide backbones confers restriction on their structure.105 Thus, depending 
on the methylation pattern, part of a liner peptide can be partially flexible. The 1H NMR 
showed a set of minor peaks along the larger peaks, especially the N-methyl and benzylic 
proton peaks were split to generate minor peaks (δH = 2.85, 2.92, 2.95, 3.10, 3.87). This 
observation made us believe in the presence of another conformer of naranjamide. Presence 
of a major and a minor conformer is possible since naranjamide has a flexible and a rigid 
portion. The flexible part, the freely rotating benzyl moiety at the C-terminal, may spatially 
interact with the other part of the molecule and result in a major and minor conformer. 
Overlapping peaks and intricate splitting patterns made it difficult to determine the 
multiplicity, calculate coupling constants for correlated protons, and integrate peaks to 
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identify the actual number of protons. However, COSY, HSQC, HMBC, and NOESY 
spectra helped to build correlations in each spin system, and connections were made from 
each spin system. To confirm the configuration of each stereocenter, a total synthesis of 
naranjamide (2.5) was attempted to compare the NMRs of both natural and synthetic 
naranjamide and validate its bioactivity.  
Table 2.1: NMR data of Naranjamide (2.5). 
C/H No. δCa δH (multiplicity, J in Hz) COSY HMBC NOE 
2  169.18   
 
 
4 143.02 7.77 (d, 3.3) 5   
5 119.73 7.36 (d, 3.3) 4   
6 54.34 6.60 (dd, 11.5, 5) 
 
6a 2, 6a, 7a 6a, 6b2’, 7a 
6a 36.05 3.69 (dd, 15, 5) 3.30 (dd, 
15, 11.5) 
6 6, 6b1¢, 6b2¢  










129.24 7.39 6b2¢, 
6b6¢ 
  
6b4¢      
7a 29.75 2.88  6, 8 6, 6a, 9, 0.69 
8 169.91   
 
 
9 58.29 5.06 (d, 2.7)  9a 8, 10a  
9a 27.10 2.32 (m) 9, 9b, 
9c 
  
9b, 9c 15.41, 
17.47, 
0.69, 0.93 (m) 9a   
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10a 29.56 2.46 (s)  9, 11 9 
11 169.74   
 
 
12 56.34 5.08 (d, 10.5) 12a 13a  
12a 32.44 2.07 (m) 12, 0.68  13 
12b      
12c      
12d      
13a 30.16 3.04 (s) 12 12, 14 0.68, 0.84, 
12, 15, 15a, 
2.07 
14 172.60     
15 53.32 4.85 (dd, 5.4) 16, 15a 14 15a, 13a, 
15a, 16,  





0.92, 1.01 (m) 15a   
16 NH 
 
6.95  15  18, 20  
17 169.77 
 
   
18 76.50 2.49  18  
18bc 42.79 2.30 s, 6H  
 
16, 18, 19 
19 27.68 2.12 20, 21 18 20, 21 
20 17.45 0.95  19, 20 19, 21 
21 20.05 1.03  20, 19 19, 20  
aC-13 data are extracted from HSQC spectra. 
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2.3. Peptide synthesis 
Re-creating the work of nature has always been a well-perceived challenge among 
organic chemists. The challenge of imitating nature inspired the first simple peptide bond 
formation by Theodor Curtius in 1881 and later by Emil Fischer in 1902, when they 
synthesized benzoylglycyl-glycine and ethoxycarbonylglycyl-glycine ethyl ester 
respectively.106-108 Since then, peptide synthesis became one of the most sought synthetic 
targets, but difficulties emerged in the synthesis of even simple and well-defined peptides. 
On the bright side, obstacles brought a surge in efforts to methodology development for 
peptide synthesis.108 The isolation of oxytocic pituitary peptide hormone, oxytocin, its 
structure determination and, its total synthesis was inspirational in the collective approach 
towards the development of peptide synthetic procedures.109-112 Though the early scientists 
were motivated by the philosophy of recreating what nature makes, methodology and 
strategic development in peptide synthesis have enabled researchers to tweak natures 



























Peptide synthesis is principally the formation of an amide bond between a carboxyl 
group and an amine group of two amino acids. The bond formation requires activation of 
the carboxylic acid group of an amino acid (Scheme 2.1), where an electron-withdrawing 
atom or group (X) will be attached to the acid (AA1). Without the activation, this bond 
formation is not possible spontaneously at room temperature. Because elevated 
temperature is required to facilitate the dehydration during the amide bond formation at 
which the stability of the synthesized compound might be compromised.113 The activating 
group improves the electrophilicity of the AA1 carbonyl group and enables the incoming 
nucleophile, which is the amine of a second amino acid (AA2), to attack efficiently. Good 
leaving group ability of the X facilitates the collapse of the tetrahedral intermediate (THI) 
and thus forms the peptide bond.  
Peptide coupling reagents serve the role of the activating group. A large number of 
various coupling reagents have been developed for this purpose.114 However, peptide 
coupling reaction to synthesize a simple dipeptide (AA1- AA2) following Scheme 2.1 will 
end up in a reaction mixture with multiple products with a different number of amino acids 
arranged randomly. The reaction mixture may or may not have the dipeptide AA1- AA2 in 
the mix. This random coupling happens because of a lack of any control over the reaction, 
and there are numerous combinations of the activated electrophile and incoming 




For example, the first amino acid AA1 may self-condensed and gives the dipeptide 
AA1-AA1. Besides, they may be further activated on their free C-terminus, or they may act 
as the nucleophile on their free N-terminus and form another peptide bond with either AA1, 
AA2, or AA1-AA1 again. Such a polymerization reaction may go on and on. Researchers 
developed the strategic use of easily cleavable protecting groups to eliminate this problem 
of uncontrolled polymerization. So, the reaction is designed in a way that, N-terminus of 
AA1,  C-terminus of AA2, and any other reactive group in the side chain will be masked 
with protecting groups. Once the desired bond is formed, the protecting groups will be 
cleaved to get the target molecule (Scheme 2.2).  
2.3.1. Amide bond in Medicinal Chemistry 
Amide bond formation is not only crucial for protein, and peptide synthesis, but 
also various compounds of therapeutic importance like peptoids, oligocarbamates, 
oligoamides, polyenamides, benzodiazepines, diketopiperazines, and hydantoins possess 



























bond donating properties. Also, the reactivity of an amide can be modified by several 
factors like steric and electronic effect by neighboring groups, and strain on the bond. 
Overall, the amide is an attractive functional group in drug design. Perhaps, one of the 
well-known example (Figure 2.4) is the inhibition of cell wall transpeptidase enzyme of 
gram-positive bacteria by penicillins.116-117  
Transpeptidase enzyme is a serine protease that catalyzes the last step of bacterial 
cell wall peptidoglycan synthesis, where two polysaccharide chains are crosslinked by a 
short peptide composed of unnatural (R)- (or D-) amino acids. The crosslinking happens 
when N-terminus glycine of a pentaglycyl moiety forms a peptide bond with the D-Ala-D-











































Figure 2.4: Mechanism of action of penicillin (modified).118-119
 47 
Penicillin acts in this step by mimicking the structure of D-Ala-D-Ala. So, the 
transpeptidase enzyme mistakenly takes penicillin as a substrate. Penicillin irreversibly 
inhibits the enzyme when the Serine OH group of the active site covalently attacks the 
highly reactive ß-lactam ring. ß-lactams are highly strained cyclic amide that acts as a good 
electrophile, where nucleophilic attack opens the lactam ring to relieve the strain. Since 
penicillin possesses the cyclic structure, it does not split into two parts and leaves the active 
site. Instead, it masks the newly formed ester bond between serine and penicillin at the 
active site so that water or any other nucleophile cannot cause hydrolysis. Once the enzyme 
is covalently linked with penicillin, i.e., acylated, it cannot catalyze the crosslinking 
further, resulted in leaky cell wall.118-119 
One recent example (Figure 2.5) of incorporating amide in chemical structure to 
play a role in target binding is the dual orexin receptor antagonist Lemborexant (2.6), 
approved to treat insomnia.120-121 Two aromatic portions (amidopyridine and pyrimidine) 
of the molecule are in cis-configuration from the central cyclopropyl ring and occupy a 
hydrophobic pocket in the receptor. The role of the amide here is to form the H-bond with 





The ubiquity of the amide bond is apparent in clinically approved drugs. In 2019, 
the FDA approved 48 drugs in various therapeutic categories.120 After studying the 
structures of these approved drugs, 37 are small molecules (including six small molecules 










Figure 2.5: Lemborexant (2.6) and H-bonding with Glutamine (Use of this image is permitted by 

































































amide bond, and are approved for treating various types of cancer, cystic fibrosis, 
migraines, insomnia, and urinary tract infection  
A review of chemical transformations used by three major pharmaceutical 
companies (GSK, Pfizer, and AstraZeneca) identified amide bond formation is the most 
ubiquitous reaction used by medicinal chemists.123 The reviewers found that amide bond 
formation accounted for 16% of all reactions pursued in the pharmaceutical industry. And 
they recognized the availability of a plethora of amide formation methodologies, which 
resulted from the development in the field of peptide synthesis, as one of the main reasons 
for amide formation being at the top among all reaction categories.  
2.3.2. Peptide coupling reagents 
Peptide coupling can be carried out in the solution or the solid-phase (SPPS).  In 
both processes, peptide coupling reagents facilitate the peptide formation by activating the 
carboxylic acid. Based on the activation method, two strategies are applied: (i) in situ 
activation and (ii) an activated species can be prepared and isolated before the coupling 
step. However, activation comes with the limitations of chirality loss of the activated amino 
acid and generation of unwanted side products. Two significant pathways (Scheme 2.3) 
have been identified for the loss of chirality: (i) direct enolization (path A) and (ii) 
oxazolone formation (path B).124  
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Major side products generated in peptide coupling reactions are N-carboxy 
anhydride, diketopiperazine, and guanidine. The latter is particularly generated with 
uronium coupling reagents.125 Thus, strategies like using additives, careful selection of 
base, and using appropriate protecting groups are employed to eliminate or minimize these 
obstacles while designing a peptide coupling reaction. A comprehensive chemical review 
El-Faham and Albericio124 has described various collection coupling reagents, including 
carbodiimides, phosphonium salts, aminium/uronium salts, anhydrides, active esters, 
acylazoles, acyl azides, acyl halides, organophosphorus reagents, organosulfur reagents, 
triazines, pyridinium coupling reagents, and polymer-supported reagents. Discussing all of 
them is beyond the scope of this dissertation. Thus, the following section will discuss the 
most commonly used peptide coupling reagents, i.e., carbodiimides (2.7), phosphonium 
(2.8), and ammonium salts (2.9), which I also used practically in my synthetic approaches.  
3.2.1. Carbodiimides 
 
Dicyclohexylcarbodiimde (DCC) (2.25; Figure 2.9) is the most commonly used 
carbodiimide, which was first introduced by Sheehan in 1955.126 The carbodiimide (2.7) 








Figure 2.6: Commonly used peptide coupling reagents.
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activates (Scheme 2.4) the corresponding carboxylic acid (2.10) by forming O-acylisourea 
(2.11), which is highly reactive to execute the coupling reaction with the corresponding 
amine (2.12) to create the peptide (2.13) (Pathway A). There two other pathways that the 
O-acylisourea can follow to form the peptide: (i) forming a symmetrical anhydride (2.14) 
by reacting with a second molecule of carboxylic acid when excess carboxylic acid is used 
(Pathway B); (ii) forming an oxazolone (2.15), which is less reactive and can undergo 
racemization (Pathway C).124  
 
Scheme 2.4 







































The high reactivity of O-acylisourea (2.11) also leads to an undesirable side 
reaction by forming N-acylurea (2.16) via rearrangement (Pathway A; Scheme 2.5). The 




Cleverly, Kong, and Geiger have solved this problem by introducing N-
hydroxyderivatives (HOXt) as additives.127 They used hydroxy benzotriazole (HOBt, 2.12) 
in their seminal paper of using additives to suppress side reactions HOBt (2.17) is a 






































nucleophile and forms (Path B; Scheme 2.5) the corresponding active Bt ester (2.18) with 
the highly reactive O-acylisourea (2.11) by a reaction faster than the rearrangement 
reaction to form N-acylurea (2.16). The formed ester (2.18) is reactive enough to undergo 
the aminolysis and formed the peptide (2.13, Pathway B, Scheme 2.5). Also, the use of 
HOXt additives prevent the formation of oxazolone mediated peptide coupling as well and 
thus retain the stereo configuration of the alpha carbon as well.128  
 
Introduction of DCC/HOBt combination enhances the scope of carbodiimide 
reagents and various other HOXt additives (Figure 2.7) like 1-hydroxy-7-azabenzotriazole 
(HOAT; 2.19),129 3,4-dihydro-3-hydroxy-4-oxo-1,2,3,-benzotriazole (HODhbt; 2.20),127 




























Figure 2.7: Additives used in peptide couplings
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hydroxy-1H1,2,3 triazole-4-carboxylate (HOCt; 2.22),131 and ethyl-2-cyano-2-
(hydroxyimi-no)acetate (Oxyma; 2.23).132 Similar nucleophilic additive role can also be 
performed by DMAP (2.24).133 
 
Among the carbodiimides, DCC (2.25) is the most commonly used reagent for 
SPPS using tert-butyloxycarbonyl (Boc) chemistry. The urea byproduct, N, N-
dicyclohexylurea (DCU), is only soluble in trifluoroacetic acid and thus makes the removal 
of DCU easy while removing the Boc protection using TFA. However, the same reason 
makes DCC useless in SPPS using fluorenylmethyloxycarbonyl (Fmoc) since it cannot be 
filtered off from the reaction medium or washed off with common organic solvents. In 
solution-phase synthesis, traces of DCU retains in the system even after extensive 
chromatographic separation. Depending on the synthetic strategy, better coupling reagents 
have substituted DCC.114, 114 N, N’-diisopropylcarbodiimide (DIC; 2.26),134 N-ethyl-N’-(3-
N C
N N HCl




Figure 2.8: Commonly used carbodiimides.
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dimethyl aminopropyl)carbodiimide (EDC; 2.27),135 and N-cyclohexyl-N’ -
isopropylcarbodiimide (CIC; 2.28)136 are among the most popular. EDC is preferred for 
solution-phase synthesis since both the reagent and the urea byproduct are water-soluble 
and thus can be easily removed by an aqueous workup.   
Carbodiimide/HOXt mediated and many other coupling reagents often require the 
use of nonnucleophilic base like triethylamine (TEA), diisopropylethylamine (DIPEA), 
and N-methylmorpholine (NMM) which could enhance the preactivation step.124 In my 
synthetic approach to naranjamide, most of the peptide coupling reactions utilized the 
EDC/HOBt system because of its superiority in solution phase synthesis.  
2.3.2.2. Phosphonium salt 
The application of alkyl phosphonium salts as a coupling reagent was first 
introduced by Gawne et al. in 1969.137 But their widespread application started with the 
introduction of CloP and BroP by Castro.135 These reagents suffered the obstacle of 
racemization. When HOBt (2.17) found its application in peptide chemistry, Clop-HOBt 
fused coupling reagent, (benzotriazole-1-acyloxy)tris(dimethylamino)phosphonium 
hexafluorophosphate (BOP; 2.29), also known as Castro’s reagent,  was developed in 
1975.138 The coupling reaction (Scheme 2.6) proceed via the deprotonation of the desired 
acid first by a hindered base like TEA or DIPEA. The deprotonated acid then reacts with 
the 2.29 to generate an activated acyl phosphonium intermediate (2.30) and HOBt. 
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Activated 2.30 is highly reactive, like O-acylisourea (2.11) generated in carbodiimides 
mediated reaction (Scheme 2.4 or 2.5). So, the in situ generated HOBt readily reacts with 
the intermediate 2.30 to form the activated Bt ester (2.18; Scheme 2.6), which then coupled 
with the corresponding amine. Generation of the corresponding phosphine oxide (2.31; 
hexamethylphosphoric triamide, HMPA) facilitate the reaction to move forward.139                                                                                                                                                                                                                                                                                                                                                                                                                                                                                      
 
However, 2.31 is exceptionally toxic. The substitution of all three dimethyl 
substituents of 2.29 was replaced with pyrrolidine to get PyBop (2.32), which is equally 
effective but produce a less toxic byproduct. Both 2.29 and 2.32 are not useful for coupling 
to N-methyl amino acid. Replacing the HOBt part of 2.32 with chloride or bromide 
generates PyClop (2.33) and PyBrop (2.34), respectively. These reagents produce the 
corresponding acyl halide instead of Bt ester and allow the incoming secondary amino 
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2.3.2.3. Aminium/Uronium salts 
The first aminium reagent, O-(1H-benzotriazole-1-yl)-N,N,N’,N’-
















2.35; X = CH
2.36; X = N


































Like the phosphonium salts, aminium salts were considered initially as uranium 
type structure where aminium salts possess a positively charged carbon atom instead of the 
charged phosphorus atom. However, X-ray crystallography found these salts to exist as an 
aminium type (guadinium N-oxides) structures. In solution, both uranium and aminium 
form exist in equilibrium (Figure 2.10).  
Their mechanism of activation (Scheme 2.7) is similar to that of phosphonium 
reagents as well, and proceeds via generation of carboxyl uranium salts (2.37), followed 
by active Bt/At ester generation (2.18). The driving force for this type of reaction is the 































The azabenzotriazol derivative, 1-[Bis(dimethylamino)methylene]-1H-1,2,3-
triazolo[4,5-b]pyridinium 3-oxid hexafluorophosphate (HATU; 2.36), was developed later 
which is very efficient in sterically hindered coupling and minimize racemization.139 When 
the nonnucleophilic counterion is tetrafluoroborate, 2.35 and 2.36 are called TBTU and 
TATU, respectively. But the counterion does not influence the rate of reaction or 
racemization.125 
2.3.3. Synthetic approaches to naranjamide 
The total synthesis of naranjamide (2.5) was envisioned through a convergent route 
utilizing solution-phase peptide synthesis, where two peptide segments (left/red and 
right/blue in Figure 2.4) were coupled at the final step to generate the pentapeptide. The 
convergent route was selected because of partial methylation of peptide bonds in 
naranjamide, sparing one of the non-methylated amides. So, I aimed to synthesize the right 
peptide segment, execute the methylation of it, and then complete the final coupling 













Figure 2.11: Two segments of naranjamide (2.5) 
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Synthesis of the left segment (Scheme 2.8) started with the coupling of (S)-
dolavaline 2.39 and the methyl ester of l-valine 2.40 using EDC/HOBt. I choose 
EDC/HOBt method because of its advantages, like better solubility and easy workup, over 
other coupling reagents in solution phase synthesis.  The synthesized dipeptide 2.41 was 
then hydrolyzed under basic conditions to cleave the ester and reveal the carboxylic acid 
58. Proton NMR of 2.42 showed a singlet at 3.3 ppm, which integrated for a value of 0.25. 
Since this is the resonance region for methoxy (-OCH3) protons, we can rationalize that the 
3.3 ppm peak was originated from the methoxy protons of remaining starting material. 
However, this starting material has no way to undergo the subsequent reaction, i.e., 






Conditions: (a) 1.1 equiv EDC.HCl, 1.1 equiv HOBt, 3 equiv DIPEA,  CH2Cl2, 0°C to rt, 























Synthesis of the right segment (Scheme 2.9) started with the coupling of t-Boc 
protected l-isoleucine 2.43 with methyl ester l-valine 2.40 using EDC/ HOBt. The 
synthesized dipeptide 2.44 was then hydrolyzed under basic conditions to cleave the ester 
protection. The generated carboxylic acid 2.45 was next coupled with the hydrochloride 
salt of (S)-dolaphenine 2.46 using EDC/HOBt. The tripeptide 2.47 was then permethylated 
Scheme 2.9 
 
Conditions: (a) 1.1 equiv EDC.HCl, 1.1 equiv HOBt, 3 equiv DIPEA, CH2Cl2, 0°C to rt, 
Overnight; (b) 3 equiv NaOH, MeOH, 3h, reflux; (c) (S)-dolaphenine (2.46), 1.1 equiv 
EDC.HCl, 1.1 equiv HOBt, 3 equiv DIPEA, CH2Cl2, 0°C to rt, 16 h; (d) (i) 25 equiv NaH, 
N2, THF, 0°C, 2h; (ii) excess MeI, N2, 0°C to rt, 22 h; (e) Trifluoro acetic acid: CH2Cl2 






















































according to the method described by Snchez et al.48 in the synthesis of almiramide 
derivatives. Using methyl iodide and sodium hydride as the base, 2.48 was synthesized. 
The proton NMR of 2.48 became complex and revealed a similar pattern that exhibited in 
the proton NMR of 2.5. Characteristic N-methyl peaks appeared in between 2.4-3 ppm. 
Also, the presence of more than one conformer was evident from the COSY of 2.48, where 
we can see the correlation of an alpha proton at 6.6 ppm with two sets of benzylic protons 
located in between 3-4 ppm.  MS data confirmed the structure of 2.48 (Figure 4.2), where 
I found the [M+Na+] peak at 581.8 (Target mass: 558.32).  At the final step in a one-pot 
reaction, the t-Boc protecting group of permethylated peptide 2.48 was removed with TFA 
to reveal the secondary amine followed by coupling with 2.42.   
In the final coupling step, several attempts (Table 2.2) were made to couple 
deprotected 2.48 and 2.42. Coupling reactions using EDC/HOBt at varying conditions were 
found unsuccessful. Peptide coupling reactions with a hindered secondary amine are less 
favorable compared to a primary amine, and both PyBrop and HATU have been found to 
act efficiently in sterically hindered coupling.139 I tried both of them, but a successful 




Table 2.2: Conditions for the final coupling step (Scheme 2.9) 
Coupling reagent (eq) Base (eq) Solvent Time Result 
EDC+HOBt (1:1) DIPEA (1) DCM 20 hrs NPF 
EDC+HOBt (1.1:1.1) DIPEA (1.1) DCM 20 hrs NPF 
EDC+HOBt (3:3) DIPEA (1.1) DCM 20 hrs NPF 
PyBrop (1) DIPEA (4) DMF+DCM 1.5 hrs NPF 
PyBrop (1.1) DIPEA (3) DCM 48 hrs NPF 
PyBrop (1.5)* DIPEA (1.8) DCM 48 hrs NPF 
HATU (1.2)** DIPEA (4.8) DMF 2 hrs 24% yield 
*NPF = No product found 
The 1H NMR data of synthetic and natural naranjamide was compared (Figure 4.9, 
Table 4.1), and the mass spectrum showed the [M+H+] at 684.44 (Figure 4.10). Though, 
proton NMR and MS data matched with that of naranjamide, the chiral purity of the 
synthetic compound was not determined. Loss of chirality of any of the alpha carbon can 
be traced back to the N-methylation reaction, where 25 equivalents of strong base was used. 
A strong base can destroy the chiral integrity of any of the alpha carbon and generate more 
than one stereoisomer. The yield of the final coupling step was 24%, which is very low as 
compared to the common HATU mediated coupling.  
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2.4. Testing for antiparasitic activity  
Synthetic 2.5 was tested against T. cruzi and P. falciparum and was found to inhibit 
the growth of both parasites with an IC50 of 9.2 μM and 2.8 μM, respectively (table 2.3). 
In contrast, the positive controls chloroquine and nifurtimox have IC50 of 19 µM and 3.1 
µM, respectively. Also, naranjamide (6) was found inactive against Leishmania donovani, 
the causative agent for leishmaniasis, but showed growth inhibition of 90.3% of the MCF-
7 cell line.  
 
2.5. Discussion 
In our biological system, N-methylation plays a crucial role in controlling 
biological function, particularly in epigenetic modification. Because of N-methylation, 
identical genotype can result in many different phenotypes.142 Similarly, the N-methylation 
Table 2.3: Bioactivity of cyanobacterial fractions and naranjamide 
Fraction 
L. donovani P. falciparum T. cruzi MCF-7 
%GI IC50 %GI IC50 %GI IC50 %GI IC50 
Crude (2002) 24.7 - 82.6 - 16.7 - 28.2 - 
2002H 13.7 - 97.5 - 75.0 - 13.6 - 
2002H4 - - 79.6 - 81.5 - - - 
Synthetic 
Naranjamide (2.5) 
- - - 2.80 - 9.20 90.3 - 
 65 
of the peptide is also found in nature to promote various physical and biological functions. 
In general, peptide drugs suffer poor pharmacokinetic profiles, i.e., short in vivo half-life 
and oral bioavailability. But N-methylation is known to improve peptide’s pharmacokinetic 
profile (resistance against protease, enhanced lipophilicity, and bioavailability).143 
Multiple N-methylation will possibly allow naranjamide to have a better pharmacokinetic 
profile. One such example is cyclosporin, which is a natural, multiply N-methylated cyclic 
peptide, and can be given orally.144 Figure 2.1 listed some marine cyanobacterial 
compounds with antiparasitic activity, and all of them are either backbone amide 
methylated (2.1- 2.3) or terminal N-alpha methylated (2.4). Naranjamide is both backbone 
amide, and N-alpha methylated. Thus N-methylation possibly helps in naranjamide’s 
antiparasitic property. It will be beneficial to see if non-methylated analogs still retain the 
antiparasitic property.  
Interestingly, naranjamide also inhibits the growth of MCF-7 cells. The dolaphenine 
moiety of 2.5 possess a thiazole ring, which is considered as the pharmacologically 
privileged structure with activities like antimicrobial, antiviral, anticancer, antifungal, 
antihistaminic and antithyroid.145-146 Thiazole containing dolaphenine has also been found 
in many bioactive marine compounds. Naranjamide’s structure closely resembles the 
structure of Dolastatin 10 (1.20), mentioned in Chapter 1, which also possesses the 
dolaphenine moiety and a peptide framework. Dolastatin 10’s cytotoxicity is mediated by 
 66 
the inhibition of microtubule assembly.103 Thus, naranjamide’s cytotoxicity can be possibly 
correlated with microtubule assembly inhibition and demands further study. This 
hypothesis also broadens naranjamide’s scope as a potential anticancer compound. 
We can hypothesize naranjamide’s possible biosynthetic origin as well considering the 
common metabolic pathways used by cyaonobacteria. They produce peptides or 
metabolites with peptidic substructure by using their non-ribosomal peptide synthetase 
(NRPS) or hybrid NRPS-polyketide synthase (PKS) machinery. Also, the N-methylation 
are executed by the N-methyl transferase (NMT).147 We can anticipate that cyanobacteria 
utilized both NRPS and NMT biosynthetic pathways to synthesize naranjamide.  
2.6. Conclusion 
In summary, a potent antiparasitic N-methylated peptide was discovered from a 
marine cyanobacterium, and a total synthesis was conducted. Naranjamide has activity 
against both T. cruzi and P. falciparum. Treatment options against T. cruzi are limited. 
Benznidazole and nifurtimox are the only drugs available on the market that treat only the 
early stage of Chagas disease, with the penalty of severe side effects and resistance 
development.148 Considering the necessity to develop anti-trypanosomal compounds, 
naranjamide can be used as the lead compound to develop well-tolerated agents for Chagas 
disease treatment. Naranjamide is more potent than nifurtimox in vitro, and future research 
will examine its in vivo efficacy, as well as its mechanism of action. The rational approach 
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to design more potent analogs against resistant strains will be the next goal to achieve. 




Chapter III: Analog synthesis 
 
3.1. Introduction 
The twentieth century has seen many significant successes in drug discovery for 
treating a wide range of diseases. These discovery campaigns approached via screening or 
rational design, including ligand-based, mechanism-based, or target-based design. 
Analysis of these compounds helped in developing design principals for small molecular 
weight compounds. Previously, most pharmaceutical companies had strictly followed these 
guidelines as a rule of thumb and triaged drug candidates.149 For example, the very well-
known design principle, “Lipinsky’s rule of five,” considers small molecules with a 
molecular weight of <500 Da as most likely to be orally active.150 There was an emphasis 
on developing orally bioavailable drugs because of patient compliance, and it was logical 
for pharmaceutical companies to exclude compounds with molecular weight >500 Da 
while screening a library of millions of molecules. Peptides easily exceed this molecular 
weight cut-off with just five amino acids. And, were generally considered as less drug-like. 
However, there are drugs in the market that violate the rule-of-five and are still orally 
active. One such molecule is cyclosporin, which is orally active despite violating all criteria 
of “rule-of-five”.144 Excluding oral bioavailability in the selection criteria resulted in the 
exploration of chemical spaces by researchers that were previously less searched for drug 
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discovery. Many peptide-based drugs like captopril (3.1), enalapril (3.2), tirofiban (3.3) 
and Epifibatide have reached the market (Figure 3.1) and a resurgence of interest in peptide 
drug discovery has been observed among pharmaceutical industries.151 
  
The activity of naranjamide against neglected tropical diseases has brought the 
necessity to explore its structure-activity relationship. Using the medicinal chemistry 
approach for peptide drug design, analogs were synthesized to elucidate more information 











































Figure 3.1: Marketed peptide drugs
 70 
3.2. Analog design for naranjamide 
Researchers have discovered many antiprotozoal peptides from Panamanian marine 
cyanobacteria. Viridamide A (3.5), isolated from Oscillatoria nigro-viridi, is an N-
methylated peptide with a methyl ester at the C-terminus and a methoxylated fatty acid 
with a terminal acetylene functionality at the N-terminus. Compound 3.5 exhibited an IC50 
of 5.8 μM to chloroquine-resistant P. falciparum, an IC50 of 1.37 μM to L. donovani, and 
an IC50 of 1.0 μM to T. cruzi.56, 152 Another peptide, Gallinamide A (3.6) sowed an IC50 of 
8.4 μM to chloroquine-resistant P. falciparum. It was isolated from a Schizothrix sp.85 
Compound 3.6 does not have methylation on the amide nitrogen. But, its N-terminus 
possesses the N, N – dimethyl isoleucine moiety, and the C-terminus amide nitrogen is part 





























Figure 3.2: Panamanian cyanobacterial peptide with antiprotozoal activity.
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684 Da. A review on peptide drugs by Craik et al.149 highlighted that majority of the 
approved peptide-based drugs are smaller in size (less than ten amino acid).  
This observation, together with the importance of antimalarial and antichagasic 
drug discovery and potential of Panamanian cyanobacterial peptides as antiparasitic agents, 
makes our lead molecule an attractive candidate for medicinal chemistry study.  
At this stage of the project, naranjamide’s mechanism of action or any information 
about its target is unknown. So, while synthesizing naranjamide analogs, the ligand-based 
approach was pursued, and a few considerations were made: (1) search for minimum active 
sequence of amino acids; (2) role of N-methylation; (3) role of the two terminal residues 
and (4) identify structural features that determine the selectivity between the malaria and 
Chagas parasites. Within the capacity of synthesis, the first analog synthesized was a non-
methylated version (3.5) of naranjamide, where all the amide nitrogens were non-
methylated. The importance of N-methylation in controlling drugs pharmacokinetic 
property is mentioned in chapter 2. So, my aim for this non-methylated version was to see 
the role of these N-methyl groups in altering bioactivity. Removing the N-methyls exposes 
the amide protons to form hydrogen bonds. However, these protons may or may not be 
accessible depending on the conformation of the peptide and propensity to form 
intramolecular hydrogen bonds. Early-stage peptide drug development generally starts 
with the simplification of the structure (e.g., size reduction).153 So, subsequent analogs (3.7 
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- 3.12) were synthesized with reduced chain length by decreasing one subunit at a time. 
Also, within the same chain length, valine and isoleucine substitution impact on the activity 
was explored. The simplest analog synthesized was a dipeptide containing the N,N-
dimethyl valine coupled to the dolaphenine moiety. Thiazole containing dolaphenine is a 
pharmacologically privileged structure, and many cyanobacterial antiprotozoal compounds 
are known to carry the N,N-dimethyl moiety at the N-terminus.85, 87, 141  152, 154- 155 Thus, the 
main focus was to combine the role of  N,N-dimethyl in antiprotozoal inhibition together 
with the inherent efficacy of dolaphenine. This design will be effective only if both N,N-
dimethyl, and dolaphenine binding sites are in close proximity.  
The scope of peptide lead modification is broad. Apart from N-methylation and 
chain length reduction, one common approach is alanine scanning, where each subunit is 
replaced with an alanine residue. Alanine replacement eliminates the side chain past the β-
carbon but does not change the peptide conformation. Alanine scan is a widely used 
technique in identifying the catalytic site of enzymes or functional roles of 
proteins/peptide.156 Another meaningful change that can be brought in naranjamide’s 
structure is changing its conformation. Naranjamide is a partial rigid structure because of 
N-methylation. Thus altering the N-methylation pattern will result in analogs with different 
conformation. Another effective way to rigidify linear peptide conformation is cyclization 
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by joining side chains or head to tail. Also, short-range cyclization (or a kink in the 
structure) can be achieved by substitution of a subunit with a proline residue.157  
 
 
Cyclic peptides offer several other advantages over linear structures. One key 
benefit is the avoidance of proteolysis by protease in the blood, thereby increasing their 






























































Figure 3.3: Synthesized naranjamide analogs
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thus make peptide drug able to target both cell surface and intracellular targets.158-159 The 
smallest cyclic peptides known to exist are 2,5-diketopiperazine derivatives, which are 
obtained by condensation of two amino acids.160 Naranjamide’s pentapeptide size is ideal 
for synthesizing cyclic analogs. So, naranjamide carries a considerable potential to develop 
a wide range of analogs using ligand-based drug design, which may result in compounds 
with higher activity against malaria and/or Chagas parasite. 
3.3. Synthesis of naranjamide analogs 
 
Synthesis of the proposed analogs utilized the similar peptide synthesis schemes 
described in chapter two for naranjamide. Also, intermediate 2.47 used in naranjamide 
synthesis was used as the starting point for compound 3.7 (Scheme 3.1). Synthesis of 
compound 3.7 started with the deprotection of the t-Boc protecting group of 2.47 using 





Conditions: (a) Trifluoro acetic acid: CH2Cl2 (1:1); (b) 2.42, 1.5 equiv HATU, 5 equiv 





























Synthesis of the two tetrapeptides (3.8 and 3.9; Scheme 3.2) started from the same 
starting material, (S)-dolaphenine hydrochloride (2.46). Compound 2.46 was first coupled 
with t-Boc protected l-valine (3.13) to synthesize the t-Boc protected dipeptide 3.14. t-Boc 
group of 3.14 was then deprotected using TFA, followed by the final coupling with the 
dipeptide 2.42 using EDC/HOBt to get 3.8. Compound 3.9 followed the same scheme, 
except the first coupling was performed using t-Boc protected l-isoleucine (2.43). 
Scheme 3.2 
 
Conditions: (a) 3.13, 1.1 equiv EDC.HCl, 1.1 equiv HOBt, 3 equiv DIPEA, CH2Cl2, 0°C to 
rt, 16 h; (b) Trifluoro acetic acid: CH2Cl2 (1:1); (c) 2.42, 1.5 equiv HATU, 5 equiv DIPEA, 
DMF, rt, N2, 2h. (d) 2.43, 1.1 equiv EDC.HCl, 1.1 equiv HOBt, 3 equiv DIPEA, CH2Cl2, 

















































Tripeptides 3.10 and 3.12 were synthesized from the t-Boc protected dipeptides 
3.14 and 3.15 (Scheme 3.3). In both routes, the t-Boc group was first removed by using 
TFA, and then subsequent coupling with N, N-dimethyl l-valine (2.39) yielded 3.10 and 
3.12, respectively 
Scheme 3.4 
Conditions: (a) 3.13, 1.1 equiv EDC.HCl, 1.1 equiv HOBt, 3 equiv DIPEA, CH2Cl2, 























































Conditions: (a) Trifluoro acetic acid: CH2Cl2 (1:1); (b) 2.39, 1.5 equiv HATU, 5 equiv 
DIPEA, DMF, rt, N2, 2h. 
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The dipeptide 3.12 was synthesized by coupling N, N-dimethyl l-valine (2.39) with 
(S)-dolaphenine hydrochloride (2.46) using EDC/HOBt peptide coupling reagent (Scheme 
3.4). 
3.4. Bioactivity of naranjamide analogs: 
 Synthesized analogs (3.7 to 3.12) were tested against T. cruzi, P. falciparum, and 
MCF-7 cell line, and their activities are compared in Table 3.1. We found that all analogs 
lack activity against the Chagas parasite and MCF-7 cell line. Also, their potency against 
the malaria parasite was lower in comparison to synthetic naranjamide and the positive 
standard chloroquine.  
Table 3.1: Bioactivity of naranjamide analogs 
Compound 
P. falciparum T. cruzi MCF-7 
IC50 (μM) %GI IC50 (μM) %GI 
Synthetic 
naranjamide (2.5) 
2.80 - 9.20 90.3 
3.7 14.46 12.23 - 0 
3.8 217.03 9.7 - 0 
3.9 49.44 3.68 - 26.9 
3.10 43.99 6.16 - 2.8 
3.11 23.99 10.53  0 
3.12     
Chloroquine 0.063 - - - 
Benznidazole - - 3.8  
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3.5 Discussion 
 The result obtained from the bioassay of compound 3.7 to 3.12 revealed that despite 
losing potency (IC50: 14.46 to 217.03 μM), all compounds become selective for the malaria 
parasite. Thus N-methylation of the amide is an essential feature for T. cruzi inhibition. 
Also, there is a possibility that the N-methylated version will be MCF-7 inhibitor as well. 
To thoroughly explore the role of N-methyl groups, it is required to test the N-methylated 
version.  
The highest antimalarial potency among the analogs was obtained for the 
pentapeptide 3.7 (IC50 = 217.03 μM). Antimalarial potency decreased when the peptide 
length is shortened in general. This lowering was maximum (15x) for the tetrapeptide 3.8 
(IC50 = 217.03), penultimate moiety at the C-terminus is a valine. Replacement of the 
penultimate valine with an isoleucine (3.9) increased the potency (4x; IC50 = 49.44 μM) in 
comparison to 3.8. A similar trend was observed in the tripeptide series as well. Compound 
3.10 and 3.11 contain valine and isoleucine, respectively, as the penultimate residue at the 
C-terminus. And, the potency increased by 2-fold in 3.11 (IC50 = 23.99 μM). Though all 
synthesized compounds were less potent in comparison to naranjamide, we saw a trend of 
comparative potency improvement when the penultimate residue is isoleucine instead of 
valine at the C-terminus. It can be hypothesized that, if dolaphenine binds at a specific 
region at the binding pocket, then there is a hydrophobic region in close proximity to the 
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dolaphenine binding site that can be accessed with isoleucine. Replacing this penultimate 
residue with alanine, a polar side chain, and isoleucine homolog will provide more 
information about this binding site. Besides, if such a hydrophobic site exists, a 
naranjamide analog with isoleucine at the second last position will increase the antimalarial 
potency.  
3.6 Conclusion 
The information obtained from naranjamide analogs can act as the starting point for 
further structure-activity relationship study. Non-methylated analogs seem to be malaria 
selective compounds; however, the Chagas selective features are yet to be determined. 
Also, other medicinal chemistry approaches like alanine scanning and cyclization could 
elucidate more information about the lead compounds pharmacophore and required 
features for selectivity and potency. 
  
 80 
Chapter IV: Experimental 
4.1. General 
All evaporations were carried out in vacuum with Heidolph Hei-Vap Advantage 
Rotary Evaporator. All compounds and reaction intermediates, but molecules with N, N-
dimethyl moiety, were dehydrated using MgSO4. For reaction intermediates or compounds 
with N, N-dimethyl moiety was dehydrated using Na2SO4. Labconco FreeZone benchtop 
freeze dryer was used for concentrating samples. All NMR spectra were recorded at 
400/500/600 MHz (Bruker Ultrashield™ 400, 500, and Ascend™ 600), respectively. The 
spectra were recorded in either deuterochloroform (CDCl3) or deuteromethanol (CD3OD) 
as solvent at room temperature. The following abbreviations are used to describe the peak 
patterns where appropriate: s = singlet, d = doublet, t = triplet, q = quartet, m = multiplet, 
dd = doublet of doublet, and b = broad signal. All coupling constants (J) are given in Hz. 
Mass spectra: HRMS: Thermo Scientific LTQ-XL linear ion-trap MS in ESI mode and 
Advion Expression compact MS. Accelerated chromatographic isolation was carried out 
on a Biotage Isolera One system with UV detection using HPLC grade solvent. Column 
chromatography was performed using Sorbent Technologies silica gel (230-400 mesh). 
Analytical TLC was performed using Merck silica gel 60 F254s foil plates. Analytical HPLC 
was performed on a Dionex Ultimate 3000 system using Phenomenox Kinetex C-18 HPLC 
column.  HPLC grade solvents were used for column chromatography and all reactions. 
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All starting materials and HPLC grade solvents were purchased from Fisher Scientific or 
Sigma and used without further treatment. 
4.2. Field sampling, extraction, and isolation  
An orange cyanobacterial mat was collected in July 2010 (collection code PAP-
17Jul10-1A) by hand using SCUBA at Dos Hermanas in the Portobelo National Park (on 
the Caribbean side), Panama (GPS coordinates: N 9 35.860 W 79 40.106). A voucher 
sample was taken for storage at the Smithsonian Tropical Research Institute in Panama. It 
was given a field identification of Lyngbia penificiliformis. Unfortunately, phylogenetic 
analysis was not possible because of the degradation of the sample preserved for 16s-rRNA 
extraction. A total of 800 mL of cyanobacterial samples was collected. The collected 
biomass was then stored in the sea-water/ethanol mixture at -20°C until extraction. 
The cyanobacterial mat was extracted repeatedly with a 2:1 mixture of 
dichloromethane: methanol (5 x 500 mL for each extraction) and filtered through 
cheesecloth. Organic layers obtained from each extraction were combined and 
concentrated by rotary evaporation at 25°C to obtain 4.2 g of the crude extract (2002). This 
crude extract was then subjected to flash silica gel column chromatography and separated 
into nine fractions with hexane:ethyl acetate (100:0, 80:20, 60:40, 40:60, 20:80, and 0:100) 
and ethyl acetate:methanol (75:25, 50:50, and 0:100). Fraction 2002H was further 
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fractionated into four fractions by using a Sep-Pak. Fraction 2002H4, obtained from the 
Sep-Pak separation, yielded the pure compound naranjamide (6) upon further purification 
in HPLC as fraction 2002H4D. 
4.3. Synthetic procedures  
4.3.1. Procedure for peptide coupling using EDC·HCl/HOBt  
To a round bottom flask/glass vial the amine protected carboxylic acid (1 eq), the 
carboxy protected amine (1 eq), 1-ethyl-3-(3-dimethylaminopropyl) carbodiimide 
hydrogen chloride (EDC·HCl, 1.1 eq), hydroxybenzotriazole hydrate (HOBt·xH2O, 1.1 eq) 
was added in dichloromethane (0.1 to 0.2 M) at 0°C, which resulted in a heterogeneous 
suspension. After 5 min, 3 eq of N, N-diisopropylethylamine (DIPEA), or triethylamine 
(TEA) was added to the reaction mixture, which turned it into a homogeneous solution. 
The reaction was run for 14-48 hours at room temperature, after which the reaction mixture 
was diluted with dichloromethane. Except for compound 2.41 and naranjamide analogs, 
the reaction mixture was then successively washed with 10% hydrochloric acid (3x), 
saturated sodium bicarbonate (3x), and brine (1x). The organic part was dried over 
anhydrous magnesium sulfate, filtered, concentrated under reduced pressure, and purified 
by flash silica column chromatography.  For compound 2.41, the reaction mixture was 
washed 10% hydrochloric acid. Aqueous parts were then combined, basified with 10% 
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NaOH and extracted with dichloromethane. The pure compound was isolated using flash 
column chromatography. All the analogs (3.7 to 3.12) were purified by using flash 
chromatography described in section 4.4. 
4.3.2. Procedure for ester hydrolysis 
To a 100 mL round bottom flask, the carboxy protected peptide (1 eq) was dissolved 
in methanol (0.2 M). Sodium hydroxide (3-5 eq) was added, and the reaction was run for 
3 hours under reflux condition at 90-95° C. After that, the reaction mixture was 
concentrated under reduced pressure to evaporate all methanol, dissolved in water and 
acidified with hydrochloric acid. For compound 2.45, the hydrolyzed product was then 
extracted with ethyl acetate (3x15 mL). The organic part was dried over anhydrous 
magnesium sulfate, was filtered, and was concentrated under reduced pressure. Due to the 
zwitterionic nature of compound 2.42, the acidified solution was dried completely. The 
solid residue was then suspended in acetone and filtered to remove undissolved NaCl, 
which was generated due to acidic workup. The acetone soluble fraction was then dried 





4.3.3. Procedure for t-Boc deprotection 
The t-Boc-protected amine (1 eq) was treated with a mixture of trifluoracetic acid 
and dichloromethane (1:1; 0.01 M) for 2 hours. The solvent was removed in vacuo, and the 
crude compound was then directly transferred for the next step. 
4.3.4. Procedure for methylation 
To a solution of the t-Boc -protected peptide (1 equiv) in dry THF (0.15 M) was 
added NaH (60% dispersion in mineral oil, 25 eq), and the solution was stirred under 
nitrogen at 0° C for 2 h. Methyl iodide (50 eq) was added dropwise, and the resulting 
solution was stirred to room temperature for a further 22 h. The reaction mixture was 
quenched with dropwise addition of water and extracted with ethyl acetate, dried over 
anhydrous magnesium sulfate, and concentrated under reduced pressure. The resulting 
yellow or colorless oil was purified by flash silica column chromatography (1:99 methanol: 
dichloromethane) to yield methylated peptide. 
4.3.5. Procedure for coupling using HATU 
In a reaction vial, containing the dried t-Boc removed 2.48 (22 mg, 0.05 mmol, 1 
eq),  was added the acid (2.42, 12 mg, 0.05 mmol, 1 eq), DIPEA (26 μl, 0.15 mmol, 3 eq) 
and HATU (38 mg, 0.1 mmol, 2 eq) and dimethyl formamide (DMF). The reaction mixture 
was stirred at room temperature overnight. The reaction mixture was then dried using high 
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vacuum and purified by automated flash chromatography using Biotage KP-Sil SNAP 
Cartridge and methanol: dichloromethane mobile phase (1:99 to 6:94) to yield 2.5. 
4.4. Synthesis and characterization 
4.4.1. Methyl dimethyl-L-valyl-L-valinate (2.41)  
Following the procedure of peptide coupling described in section 4.3.1, compound 
2.41 was isolated by flash silica column chromatography using 3% methanol in 
dichloromethane as a white solid. Yield: 436.93 mg, 88%. 1H NMR (500 MHz, CDCl3): 
0.92-1.02 (12 H, m, 4xCH3), 2.11 (1H, m, CH), 2.21 (1H, m, CH), 2.29 (6H, s, 2xCH3), 
2.50 (1H, d, CH), 3.74 (3H, s, CH3), 4.57 (1H, q, CH), 6.88 (1H, d, NH); 13C NMR (126 
MHz, MeOD):15.7, 17.1, 18.4, 18.5, 27.2, 30.1, 41.1, 72.5, 165.9. 4.6.7.  
4.4.2. Dimethyl-L-valyl-L-valine (2.42) 
Following the procedure of ester hydrolysis described in section 4.3.2, compound 
2.42 was isolated by flash silica column chromatography using 3% methanol in 
dichloromethane as a colorless solid. Yield: 280.3 mg, 65%. 1H NMR (500 MHz, MeOD): 
1.01 (9H, d, 3xCH3), 1.17 (3H, d, CH3), 2.24 (1H, m, CH), 2.42 (1H, bs, CH), 2.92 (6H, 
s, 2xCH3), 3.92 (1H, s, CH), 4.38 (1H, d, CH), 8.67 (1H, d, NH); 13C NMR (126 MHz, 




4.4.3. Methyl (tert-butoxycarbonyl)-L-isoleucyl-L-valinate (2.44) 
Following the general procedure of peptide coupling described in 4.3.1, compound 
2.44 was synthesized and isolated by flash silica column chromatography using 15% ethyl 
acetate in hexane as a white solid. Yield: 430 mg, 83%; 1H NMR (400 MHz, CDCl3): 0.92 
– 0.97 (12H, m, 4xCH3), 1.17 (1H, m, CH), 1.46 (9H, s, 3xCH3), 1.53 (1H, m, CH2), 1.89 
(1H, m, CH2), 2.19 (1H, qd, CH), 3.76 (3H, s, CH3), 3.96 (1H, m, CH), 4.57 (1H, dd, CH), 
5.05 (1H, dd, NH), 6.36 (1H, dd, NH); 13C NMR (126 MHz, CDCl3) : 11.3, 15.4, 17.7, 
18.9, 24.8, 28.3, 31.1, 36.9, 52.0, 57.0, 59.3, 79.7, 155.8, 171.8, 172.1 
4.4.4. (Tert-butoxycarbonyl)-L-isoleucyl-L-valine (2.45) 
Following the general procedure of ester hydrolysis described in 4.3.2, compound 
10 was obtained after drying as a white solid. Yield: 390 mg, 96%; 1H NMR (400 MHz, 
CDCl3): 0.88-0.99 (12 H, m, 4xCH3), 1.16 (1H, m, CH), 1.45 (9H, s, CH), 1.56 (1H, m, 
CH2), 1.83 (1H, m, CH2), 4.05 (1H, t, CH), 4.62 (1H, dd, CH), 5.38 (1H, m, NH), 6.91 (1H, 
m, NH). 13C NMR (126 MHz, MeOD) δ 10.7, 15.2, 17.3, 18.9, 24.9, 28.2, 28.3, 31.0, 36.3, 






Following the general procedure of peptide coupling described in 4.3.1, compound 
2.47 was synthesized and isolated by flash silica column chromatography using 25% ethyl 
acetate in hexane as a white solid. Yield: 356.6 mg, 50%; [α]D27 -35.50 (c 0.9, DCM); 1H 
NMR (400 MHz, CDCl3): 0.79-0.96 (12H, m, 4xCH3), 1.15 (1H, m, CHH), 1.47 (9H, s, 
3xCH3), 1.54 (1H, m, CHH), 1.90 (1H, m, CH), 2.13 (1H, m, CH), 3.31 (2H, dd, CH2), 
3.95 (1H, t, CH), 4.40 (1H, dd, CH), 5.43 (1H, d, NH), 5.65 (1H, dd, CH), 6.64 (1H, d, 
NH), 7.10 (1H, m, CH, aromatic ring), 7.22 (4H, m, 4xCH, aromatic ring), 7.45 (1H, dd, 
NH), 7.78 (1H, d,  CH, aromatic ring)   ; 13C NMR (126 MHz, CDCl3): 10.7, 15.2, 17.3, 
18.9, 24.9, 28.2, 31.0, 36.3, 56.8, 59.2, 80.2, 156.4, 173.0, 174.3. MS: m/z calcd for [M+, 
C27H40N4O4S+]: 516.28; found: 516.7.  
4.4.6. Tert-butyl methyl((2S,3S)-3-methyl-1-(methyl((S)-3-methyl-1-(methyl((S)-2-phenyl-
1-(thiazol-2-yl)ethyl)amino)-1-oxobutan-2-yl)amino)-1-oxopentan-2-yl)carbamate (2.48) 
Following the procedure described for methylation in 4.3.4., compound 2.48 
obtained as a colorless oil. Yield: 73.5 mg, 82%. [α]D27 -264.0 (c 0.3, DCM) NMR data are 
assigned on the basis of 2D correlations. 13C data are extracted from HSQC and HMBC 
spectra; %  1H NMR (500 MHz, CDCl3): Mixture of rotamers; major rotamers: 0.70 (6H, 
m, 2xCH3), 0.72 (6H, m, 2xCH3), 1.45 (9H, s, 3xCH3), 2.01 (1H, m, CH), 2.30 (1H, m, 
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CH), 2.46 (3H, s, CH3), 2.70 (3H, s, CH3), 2.87 (3H, s, CH3), 3.30 (1H, m, CHH), 3.69 
(1H, d, CHH), 4.58 (1H, d, CH), 5.05 (1H, d, CH), 6.62 (1H, d, CH), 7.27 (2H, d, CH, 
aromatic ring), 7.37 (4H, m, aromatic ring), 7.77 (1H, d, aromatic ring). 13C NMR: 10.9, 
14.8, 16.8, 18.9, 20.0, 28.3, 29.7, 29.4, 29.9, 35.9, 54.3, 58.1, 58.5, 77.3, 120.1, 128.6, 
129.4, 142.6, 169.5, 170.2, 170.6;  [M+Na+, C30H46N4O4NaS+]: 581.76; found: 580.7. 
4.4.7. (2S,3S)-2-(2-((S)-2-(dimethylamino)-3-methylbutanamido)-N,3-
dimethylbutanamido)-N,3-dimethyl-N-((S)-3-methyl-1-(methyl((S)-2-phenyl-1-(thiazol-2-
yl)ethyl)amino)-1-oxobutan-2-yl)pentanamide (naranjamide, 2.5). 
Following the procedure described for HATU coupling, compound 5 was obtained 
as a white solid with an overall yield of 5%. [α]D27 -506.7 (c 0.12, DCM) MS data and 




Following the general procedure of peptide coupling described in section 4.3.1, 
compound 3.14 was synthesized. The impure mixture was a yellow oil. Successive column 
purification using Biotage KP-Sil SNAP Cartridge and methanol: dichloromethane (1:10) 
yield fractions with the target molecule and some impurities. All fractions were recombined 
and then purified as a white solid by manual flash silica column using 2 % methanol in 
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dichloromethane. Yield: 179.8 mg, 89%. 1H NMR (500 MHz, CDCl3): 0.83-0.92 (6H, m, 
2xCH3), 1.46 (9H, s, 3xCH3), 2.12-2.21 (1H, m, CH), 3.32 (2H, t, CH2), 3.94 (1H, t, CH), 
4.95 (1H, bs, NH), 5.65 (1H, dd, CH), 6.75 (1H, bs, NH), 7.10 (2H, d, 2xCH, aromatic 
ring), 7.22-7.26 (4H, m, 4xCH, aromatic ring), 7.76 (1H, d,  CH, aromatic ring) 
4.4.9. Tert-butyl ((2R,3S)-3-methyl-1-oxo-1-(((S)-2-phenyl-1-(thiazol-2-
yl)ethyl)amino)pentan-2-yl)carbamate (3.15) 
Following the general procedure of peptide coupling described in section 4.3.1, 
compound 3.14 was synthesized and isolated by flash silica column chromatography using 
3% methanol in dichloromethane. Yield: 116.7 mg, 56%. 
4.4.10. (S)-2-(dimethylamino)-3-methyl-N-((S)-3-methyl-1-(((S)-3-methyl-1-oxo-1-(((S)-2-
phenyl-1-(thiazol-2-yl)ethyl)amino)butan-2-yl)amino)-1-oxobutan-2-yl)butanamide (3.8) 
Following the general procedure of peptide coupling described in section 4.3.1, 
compound 3.8 was synthesized and isolated by flash silica column chromatography using 
0.5% to 2% methanol in dichloromethane. Yield: 41.1 mg, 65%. 
4.4.11 (2S,3S)-2-((S)-2-((S)-2-(dimethylamino)-3-methylbutanamido)-3-methyl 
butanamido)-3-methyl-N-((S)-2-phenyl-1-(thiazol-2-yl)ethyl)pentanamide (3.9) 
Following the general procedure of peptide coupling, compound 3.9 was 
synthesized and purified as a white solid by flash column chromatography using 5% 
methanol in dichloromethane. Yield: 15.9 mg; 25%. 1H NMR (500 MHz, CDCl3): 0.80-
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085 (6H, m, 2xCH3). 0.90-0.98 (9H, m, 3xCH3), 1.04 (3H, d, Ch3), 1.28 (2H, m, obscured, 
CH2), 1.92 (1H, m, CH), 2.13 (1H, m, CH), 2,29 (6H, s, 2xCH3), 2.54 (1H, d, CH), 3.32 
(2H, d, CH2), 4.21 (1H, t, CH), 4.35 (1H, dd, CH), 5.65 (1H, dd, CH), 6.39 (1H, d, NH), 
6.97 (2H, m, b, 2xNH), 7.12 (2H, d, 2CH, aromatic ring), 7.21-7.27 (4H, m, 4xCH, 
aromatic ring), 7.74 (1H, d,  CH, aromatic ring)   
4.4.12. Synthesis of (S)-2-(dimethylamino)-3-methyl-N-((S)-3-methyl-1-oxo-1-(((S)-2-
phenyl-1-(thiazol-2-yl)ethyl)amino)butan-2-yl)butanamide (3.10) 
Following the general procedure of peptide coupling described in 4.3.1, compound 
3.10 was synthesized and purified as a white solid by flash column chromatography using 




Following the general procedure of peptide coupling described in 4.3.1, compound 
3.11 was synthesized and purified as a white solid by flash column chromatography using 
5% methanol in dichloromethane. Yield: 20.7 mg; 39%. 1H NMR (500 MHz, CDCl3): 0.85-
0.92 (9H, m, 3xCH3), 1.02 (3H, d, CH3), 1.09-1.16 (1H, m, CHH), 1.44-1.54 (1H, m, 
CHH), 1.86-1.93 (1H, m, CH), 2.11 (1H, dt, CH),  2.23 (6H, s, 2xCH3), 2.48 (1H, d, CH), 
3.30 (2H, d, CH2), 4.34 (1H, dd, CH), 5.62 (1H, dd, CH), 6.87 (1H, d, NH), 6.90 (1H, d, 
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NH), 7.10 (2H, dd, 2CH, aromatic ring), 7.18-7.24 (4H, m, 4xCH, aromatic ring), 7.75 (1H, 
d,  CH, aromatic ring) 
4.4.14. Synthesis of (S)-2-(dimethylamino)-3-methyl-N-((S)-2-phenyl-1-(thiazol-2-
yl)ethyl)butanamide (3.12) 
Following the general procedure of peptide coupling described in 4.3.1, compound 
3.12 was synthesized and purified as a white solid by preparative HPLC. Yield: 17.3 mg; 
54%. 1H NMR (500 MHz, CDCl3): 0.68 (3H, d, CH3), 0.92 (3H, d, CH3), 2.19- 2.05 (1H, 
m, CH),  2.16 (6H, s, 2xCH3), 2.43 (1H, d, CH), 3.30 (1H, dd, CHH), 3.39 (1H, dd, CHH), 
5.73 (1H, dd, CH), 6.97 (1H, d, NH), 7.18-7.28 (4H, m, 6xCH, aromatic ring), 7.77 (1H, 
d,  CH, aromatic ring). 
 Due to loss of data, spectroscopic information for 3.8, 3.10, and 3.15 are not 
presented here. 
4.5. Bioassays 
4.5.1. Chagas disease bioassay 
Trypanosoma cruzi bioassays were performed using a colorimetric method, and the 
inhibition of parasite growth was assessed by the expression of the reporter gene for b-
galactosidase (b-Gal) in the recombinant Tulahuen clone C4 of T. cruzi from The American 
Type Cell Collection (ATCC). Assays were performed in duplicates on the amastigote 
stage, which is the intracellular form of the parasite infecting African green monkey kidney 
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(Vero) cells, exposed during 120 h to different concentrations (10, 2, and 0.4 µg/mL) of 
the test compounds at 37°C under an atmosphere of 5% CO2 in air. The resulting color 
from the cleavage of chlorophenol red-b-D-galactoside (CPRG) by b-Gal expressed by the 
parasite was measured at 570 nm. The concentration that inhibited 50% expression of b-
Gal (IC50) was calculated by log regression of the obtained optical density values and 
compared with the untreated controls. Nifurtimox was used as a positive control (IC50 2-5 
µg/ml). 
4.5.2. Malaria bioassay 
The antiplasmodial activity was evaluated using a fluorometric method based on 
the detection of parasite DNA with the fluorochrome PicoGreen. The chloroquine-resistant 
strain Indochina W2 (a generous gift of The Walter Reed Army Institute of Research, Silver 
Spring, MD) of Plasmodium falciparum was used for the crude extract and subsequent 
fractions. For the synthetic product,  the chloroquine-sensitive HB3 strain obtained from 
the (Malaria Research and Reference Reagent Resource Center (MR4, Manassas, VA, 
USA) was used. All initial screenings were performed at 10 µg/mL. The IC50 value was 
calculated by normal regression of the resulting inhibition percentages at 0.08, 0.4, 2, and 
10 µg/mL. Parasites were maintained in vitro by a modification of the method of Trager 
and Jensen,17 synchronizing the parasites with alanine, as described in Almanza et al.18 
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Chloroquine was used as a positive control (IC50 80-100 nM for W2 and 15-26 nM for 
HB3).  
4.5.3.  Leishmania bioassay 
Axenically grown (cell-free) amastigotes of Leishmania donovani WR2801, a kind 
gift from Max Grogl (Experimental Therapeutics Division, Walter Reed Army Institute of 
Research, Silver Spring, MD, USA), were used to assess parasite growth and survival. 
Samples were tested in duplicates at 10 µg/mL. The results were expressed as a percentage 
of growth inhibition (GI) compared to controls. Samples that showed over 70% GI were 
considered active and were then assayed at four different concentrations (0.08, 0.4, 2, and 
10 µg/mL) to determine IC50 values. Amphotericin B was used as a positive control with 
an IC50 value response of 80-120 ng/ml.  
4.5.4. MCF-7 cell line assay 
The MCF-7 mammalian breast cancer cell line was obtained from ATCC. On the 
day before the bioassay, 5×103 cells were seeded in a final volume of 100 µl/well in 96-
well plates and incubated with RPMI-1640 supplemented with gentamicin (0.05 mg/ml), 
L-glutamine (GIBCO; 2 mM), NaHCO3 (4.6 mM), HEPES buffer (25 mM), and FBS 
(10%) at 37°C. For each bioassay, 100 µl of the extract was diluted in culture media, added 
to the cells, and incubated for 48 h at 37°C. Cells were fixed with tricholoroacetic acid 
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(50%), and treated with sulphorhodamine B (0.4%), which was allowed to react for 15-30 
min at 22°C. The cells were then rinsed with acetic acid (1%), dried, and treated with Tris-
HCl (10 mM; pH 7) for 15 min. Color intensity was read at 570 nm. The positive control 
used was adriamycin (normal IC50 value is approximately 20-50 nM). 
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4.6 Spectroscopic data for isolated and synthetic naranjamide 
 4.6.1 High-resolution ESI-MS spectrum of natural compound 2.5 
  
























Figure 4.2: MS-MS fragmentation of natural compound 2.5  via ion trap 
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 4.6.3 NMR data of natural compound 2.5 
 




Figure 4.4: COSY spectrum (CDCl3, 500 MHz) of natural compound 2.5  
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Figure 4.6: HMBC spectrum (CDCl3, 500 MHz) of natural compound 2.5 
 
 


























Table 4.1: Comparison of 1H NMR data of natural and synthetic naranjamide 
C/H No. 
δH of natural naranjamide 
(multiplicity, J in Hz) 
δH of synthetic 
naranjamide 
2   
4 7.77 (d, 3.3) 7.77 (d, 3.3) 
5 7.36 (d, 3.3) 3.36 (d, 3.3) 
6 6.60 (dd, 11.8, 4.8) 
 
6.60 (dd, 11.6, 4.9) 
 
6a 
3.69 (dd, 15, 4.9) 3.30 (dd, 
15, 11.8) 
3.69 (dd, 15.1, 4.9) 
3.29 (dd, 15.0, 11.6) 






3¢, 5¢ 7.39 7.38 
4¢ Obscured 
7a 2.87 2.87 
8   
9 5.06 (d, 2.7) 5.06 (dd, 10.8, 1.9) 
9a 2.32 (m) 2.31 (m) 
9b, 9c 0.69, 0.93 (m) 0.68, 0.96 (m) 
10a 2.46 (s) 2.43 (s) 
11   
12 5.07 (dd, 10.8, 2.7) 5.06 (dd, 10.8, 1.9) 
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13a 3.04 (s) 3.03 (s) 
14   
15 4.84 (m) 4.82 (m) 
15a 1.94 (m) 1.95 (m) 
15bc 0.92, 1.01 (m)  
16 NH 6.95 obscured 
17   
18 2.49  
18bc 2.30 (s) 2.39 (s) 
19 2.12  
20 0.95  




Chapter V:  Conclusion 
Nature directly or indirectly inspires and reveals the solution of all problems, and 
science provides the way to make these insights tangible, practical, useful, and meaningful. 
If we take away nature’s contribution from the history of drug discovery and development, 
it would have been still in its primitive stage. Nature is, by far, the richest contributor to 
drug discovery research. From ancient times to the present day, search for disease remedies 
in nature has been continued. Unfortunately, not all severe diseases get the required 
emphasis. Neglected tropical diseases (NTDs) have been known for centuries, and some of 
these lethal diseases are severely limited in terms of therapeutic options. The most 
vulnerable population to NTDs are the impoverished community of Africa and Asia, which 
do not promise a significant financial return for a successful NTD drug discovery 
campaign. Thus, most pharmaceutical companies are less interested in developing drugs 
for NTDs. No wonder that diseases like Chagas has only two drugs in the market, which 
are far from patient compliant, effective therapeutic options.  Our effort led to the discovery 
of a compound that inhibited the growth of both malaria and the Chagas parasite. Various 
potent antimalarial drugs are available in the market, and yet malaria is one of the deadliest 
diseases on this planet. Though the total number of infected population has declined in 
recent years due to vector control and other preventive measures, malaria’s severity is still 
monumental. The emergence of resistant pathogens has necessitated the discovery of new 
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antimalarials. Unlike malaria, Chagas disease is not widespread but still require new drugs 
with improved safety and efficacy since it lacks a favorable treatment option. Both malaria 
and Chagas disease are NTDs that require extensive drug discovery research in both 
academia and industry.  
The discovery of marine natural products as a source of bioactive compounds 
introduced researchers to a new stockpile of structurally intriguing molecules. Successful 
efforts have been made to take these molecules from the ocean to the shelves of the clinic. 
And, efforts should be continued to yield the maximum output from this drug source. 
Billion-year-old marine cyanobacteria are among the most attractive sources among marine 
species that produce a plethora of bioactive molecules.  Inherently, compounds from 
marine organisms are extremely potent since when released in their neighboring aquatic 
environment, despite dilution to a considerable extent, they have to function properly. 
Thus, marine cyanobacteria promise the discovery of highly potent bioactive molecules. 
The importance of NTD drug development and the potential of marine cyanobacteria as 
the drug source led to approaches that resulted in the discovery of a cyanobacterial 
secondary metabolite. 
The compound was given the name naranjamide. It is a pentapeptide with multiple 
N- methylation of the amide nitrogen and contains two unnatural amino acids at the C-
terminus and the N- terminus. From the knowledge of cyanobacterial biosynthetic 
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machinery, we can assume that naranjamide is biosynthesized via non-ribosomal peptide 
synthase and N- methyltransferase pathway.  
 The discovery of naranjamide and its bioactivity, led us to attempt the total 
synthesis of the natural product. In our attempt, we synthesized synthetic naranjamide, but 
the chiral integrity of the molecule was lost. One possible reason for this could be using a 
strong base in one of the reactions to synthesize a reaction intermediate. Interestingly, this 
synthetic version was also active against malaria and the Chagas parasite. Thus, our next 
logical approach was to explore the structure-activity relationship of naranjamide. In doing 
so, we synthesized a series of non-methylated analogs, where the peptide length was 
gradually reduced, one amino acid at a time. We found that removing all N- methyl groups 
of amide nitrogen made the analogs malaria selective, though we significantly lost the 
potency. The analogs also elucidated critical information about the neighboring adjacent 
amino acid of dolaphenine. We saw an improvement of activity when this amino acid is 
isoleucine instead of valine. This observation leads to the hypothesis that the target may 
have a hydrophobic binding pocket adjacent to the dolaphenine binding pocket and can be 
accessed by the isoleucine side chain.  
In this attempt of naranjamide synthesis, the stereo-configuration was 
compromised. It will be compelling to see how a stereochemically pure synthetic 
naranjamide behaves in bioassays. Other structural modifications are required to build up 
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a complete story of naranjamide and its requirements for activity and selectivity. Synthesis 
of more naranjamide, will also allow researchers to elucidate its mechanism of action. Once 
a target is known, an in silico process may lead to more potent analogs through the use of 
molecular modeling for design. Also, target identification will allow us to explore the key 
features that determine the selectivity between the Chagas and malaria parasites.  This 
project utilized both natural product chemistry and medicinal chemistry approaches to 
discover a potential lead for maria and Chagas disease, and obtained results can act as a 
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